



# 第三届 广州国际肿瘤学会议

The 3rd Guangzhou International Symposium on Oncology

热烈庆祝广东省抗癌协会成立30周年

## 会议指南 Conference Guide

时间: 2013年11月7-9日

Time: November 7-9, 2013

地点: 广州白云国际会议中心

Location: Baiyun International Convention  
Center in Guangzhou

### 主办单位/Sponsors:

 中山大学肿瘤防治中心  
Sun Yat-sen University Cancer Center

 美中抗癌协会 (USCACA)  
US Chinese Anti-Cancer Association

 广东省抗癌协会  
Guangdong Anti-Cancer Association

 《癌症》杂志  
Chinese Journal of Cancer (CJC)

关注学科发展前沿  
加强国内外学术交流





## 中山大学肿瘤防治中心

中山大学肿瘤防治中心由中山大学附属肿瘤医院和中山大学肿瘤研究所两部分组成。经过近五十年的不懈建设，现肿瘤防治中心已经发展成为全国医疗规模最大、学术力量最雄厚的集医疗、教学、科研、预防于一体的肿瘤学医、教、研基地之一，学科地位、综合实力已居全国领先水平，在全国尤其是广东省的肿瘤防治工作中发挥着举足轻重的作用。中心现有员工1,876人，病床数984张，设有32个业务科室，8个职能处室，2个实验研究科室。2012年门诊量达565,076人次，出院人数达51,916人次，手术10,914例，医疗业务量均居全国肿瘤专科医院前列。

该中心设有内科、血液肿瘤科、儿童肿瘤科、生物治疗中心、鼻咽科、放疗科、综合科、中医科、头颈科、神经外科、胸科、乳腺科、结直肠科、胃胰科、肝胆科、泌尿外科、妇科、麻醉科、重症医学科、影像与微创介入中心、内镜激光科、超声心电图、核医学科、病理科、分子诊断科、检验科、临床营养科、药学部、实验研究部、临床试验研究中心、预防医学部等业务科室，收治的病人来自全国各地及东南亚地区。

中山大学肿瘤防治中心是国家重点学科（肿瘤学）、国家重点实验室（华南肿瘤学国家重点实验室）、教育部重点实验室、广东省重点实验室、国家级首个抗癌药物临床实验研究基地（GCP中心）、中国中西医结合肿瘤中心、博士学位授权点、博士后科研工作流动站、广东省抗癌协会的依托单位。中心主编国家级核心期刊——《癌症》。

中心拥有一支高水平的医教研队伍，其中中国科学院院士2名，硕士生导师92名，博士生导师61名，在读研究生459人。中心的多个学科发展居国内领先水平，是中国抗癌协会鼻咽癌专业委员会、化疗专业委员会、大肠癌专业委员会，神经肿瘤专业委员会、肿瘤微创治疗专业委员会的主委单位；中国抗癌协会食管癌专业委员会、淋巴瘤专业委员会、放疗专业委员会、肝癌专业委员会的副主委单位。中心于1998年率先在全国推行肿瘤单病种首席专家负责制，组织制订各大病种多学科综合诊疗方案，可为广大肿瘤病人提供高水平的诊疗服务。

在教学方面，中山大学肿瘤防治中心为全国，尤其是广东省培养了大批的肿瘤专科人才。中心是国家级医疗继续教育基地，自1964年起卫生部委托开办全国肿瘤临床医学进修班，已为全国培养了3000多名肿瘤专业技术人才。

肿瘤防治中心作为我国较早建立的癌症防治机构，“十五”以来，积极开展科技创新、体制创新，对研究人员推行PI制，实行“滚动、竞争、开放”的体制，在科研方面取得了重大进展，共获得各级科研课题资助344项，包括“国家杰出青年基金”、“十五”国家重大科技专项、国家“863”计划及“973”计划项目及国家科技攻关项目、国家自然科学基金重点项目等；获得各类科技成果奖励15项，其中包括国家科技进步二等奖、国家自然科学基金二等奖各一项，中华医学科技奖一等奖、广东省科技一等奖各2项；中心自行研发的低熔点铅挡块技术、适形照身技术，已被广泛应用于放射治疗；国家I类新药重组人内皮抑素腺病毒抗肿瘤注射液已完成I期临床试验；生物工程人工食管已获得国家食品药品监督管理局批准，即将进入临床试验。

此外，肿瘤防治中心被国际上的SCI期刊收录发表论文数也逐年增多，主编的核心期刊——《癌症》杂志在国内外的影响力亦与日俱增。中心还是世界卫生组织（WHO）癌症研究合作单位，2003年与全美实力排名第一的安德森癌症中心（M.D.Anderson）结为姊妹医院，与瑞典、日本、法国、英国等世界先进的癌症防治机构也建立了密切联系。



## 目 录

邀请函	1
Invitation	2
大会组织机构	3
Organization	4
会议报到注册	5
Registration	5
餐饮安排	6
Repast Arrangement	6
会议日程	7
Agenda	7
专家简介	11
Expert Profile	11
会议中心功能分布图	38
Map of the Baiyun International Convention Center	38
会场分布	39
Meeting Location	39

注：信息如有变更，请以现场提示为准。

## 邀请函

为充分把握国际肿瘤学术研究动态，促进我国肿瘤学发展，加强基础与临床的紧密结合，为从事肿瘤研究和防治工作的相关学者提供交流信息的平台，由广东省抗癌协会、美中抗癌协会(USCACA)、中山大学肿瘤防治中心、《癌症》杂志(*Chinese Journal of Cancer*)联合主办，获得权威组织“国际抗癌联盟”(Union for International Cancer Control, UICC)认证的“第三届广州国际肿瘤学会议”将于2013年11月7-9日在广州白云国际会议中心隆重举行。

由中山大学肿瘤防治中心主办的“第一届广州国际肿瘤学会议”取得了圆满成功，会议代表来自美国、法国、德国、澳大利亚和中国等多个国家和地区，其中包括诺贝尔医学奖获得者——美国Fox Chase癌症中心荣誉教授Baruch S. Blumberg博士、美国MD Anderson癌症中心多位国际知名的教授、时任中国科学院副院长陈竺院士、卫生部副部长黄洁夫教授以及多位中国科学院及工程院院士、国内多家肿瘤专科医院的院长、知名专家和学者。与会者就肿瘤研究的前沿和发展的的问题进行了广泛交流，展开热烈讨论，是一次成功的国际会议。

由广东省抗癌协会、美中抗癌协会(USCACA)、中山大学肿瘤防治中心、《癌症》杂志(*Chinese Journal of Cancer*)联合主办的“第二届广州国际肿瘤学会议”于2011年5月21-22日在广州白云国际会议中心顺利举行。本次会议共邀请到来自6个国家的55位专家与会作学术报告，25个学者主持报告会。来自中国29个省市、地区共1,055位代表参会。多位国际知名肿瘤学家，及多名国内医学界两院院士和众多著名肿瘤学专家作专题学术报告，国内外顶级的学者对当前肿瘤基础、临床及转化研究中的重大问题进行了报告。该次会议内容丰富，是我国肿瘤学基础、临床和转化研究的一场高层次、高水平和高质量的国际肿瘤学盛会；这也是USCACA与国内单位在学术领域中一次有益合作的尝试，对肿瘤学研究的发展起到了积极的推动作用。

“第三届广州国际肿瘤学会议”将以“关注学科发展前沿，加强国内外学术交流”为宗旨，重点突出国际肿瘤学术研究前沿进展动态，促进中国肿瘤学研究的发展。大会拟邀请诺贝尔奖获得者、中外科学院院士和著名肿瘤学专家作大会专题学术报告，将对当前肿瘤学基础、临床及转化研究中的重大问题，包括最新研究方向、研究技术和研究成果进行报告；多个基础和临床分会场将分别报告各自研究领域中的最新研究动态、研究成果和进展。本次会议内容丰富，将是一次具有国际影响力的高水平学术盛会，必将对提高我国肿瘤学术研究水平起到积极的推动作用。

“第三届广州国际肿瘤学会议”将在著名的亚运之城广州举行。初冬的羊城依然繁花似锦、气候宜人！我们诚挚地邀请中外专家、学者参加本次大会，相互交流，共同进步，为我国肿瘤防治事业的发展不懈努力。



大会主席  
曾益新 Wei Zhang



## Invitation

Dear Visitor,

After the success of the two previous editions, we are pleased to invite you to attend the 3rd Guangzhou International Symposium on Oncology. The symposium is jointly organized by the Guangdong Provincial Anticancer Association, the US Chinese Anti-Cancer Association (USCACA), Sun Yat-sen University Cancer Center and the *Chinese Journal of Cancer*. The symposium is also under the auspices of Union for International Cancer Control (UICC). It will be held on November 7-9, 2013, at the Baiyun International Convention Center in Guangzhou, China.

This meeting is convened to address the latest advances on cancer care research and prevention, and provide an international platform for oncologists to exchange their latest progress. The 3rd Guangzhou International Symposium on Oncology will highlight international academic progress on cancer research and promote the oncologic research in China. The symposium organizing committee invite Chinese and international leading oncology investigators to share their perspective on current cancer research (basic, clinical and translational). In addition to the plenary sessions, multiple breakout sessions will focus on specific fields of clinical and basic oncology. The symposium will be the occasion of a high level academic gathering, playing an important role in promoting cancer care and research on an international scale. A brainstorm session of Basic Research, Translational Medicine, and Clinical Development of Innovative Oncology Drugs will be held at the end of this symposium, focusing on clinical and regulatory considerations in novel cancer drug development, as well as opportunities and challenges in China.

We are pleased to welcome international and national experts to participate in our symposium, so we can join our tireless efforts in the fight against cancer.

**Conference Chairs:**

Yi-Xin Zeng, MD, PhD

Professor and President,

Peking Union Medical College (Beijing, China)

Sun Yat-sen University Cancer Center (Guangzhou, China)

Vice President, Chinese Anticancer Association (CACA)

Wei Zhang, PhD

Professor and Director,

Cancer Genomics Core Laboratory, M.D. Anderson Cancer Center (Houston, USA)

Former President, US Chinese Anti-Cancer Association (USCACA)



# 大会组织机构

## 大会主席

曾益新 Wei Zhang (USA)

## 执行主席

徐瑞华

## 学术委员会

主任委员：吴一龙 宋尔卫 黄 蓬 罗荣城 崔书中

委 员：（按姓氏笔画排列）

Brian J. Druker (USA)	Carlos Arteaga(USA)	Glen N. Barber (USA)	Gregory Fuller (USA)
Hui-Kuan Lin (USA)	Jill E. Wykosky (USA)	Jingwu Xie (USA)	Joe Chang (USA)
Li Yan (USA)	Lynette Moore (USA)	Matti Nykter (Finland)	Nicholas Thatcher (UK)
Olli Yli-Harja (Finland)	Thomas J. Lynch (USA)	Van Cutsem (Belgium)	Wei Zhang (USA)
Webster Cavenee (USA)	Xiang-Xi Xu (USA)	Zhe-Sheng Chen (USA)	

丁 健 丁彦青 于世英 于金明 万德森 王 平 王建祥 车晓燕 石汉平 石远凯 卢泰祥  
史安利 戎铁华 吕有勇 任 军 庄诗美 刘芝华 刘 奇 刘 强 关新元 汤静燕 那彦群  
孙 莉 李扬秋 李恩民 杨仁杰 杨焕明 步 宏 吴沛宏 沈慧勇 宋金纲 张 宁 张 灏  
张志愿 张苏展 张晓鹏 陆道培 陈志南 陈规划 邵志敏 林东昕 林洪生 季加孚 周清华  
郑利民 赵世光 柯 杨 钦伦秀 姜小清 姜文奇 姚开泰 秦叔逵 倪泉兴 高国全  
陶 谦（香港） 黄文林 曹 亚 曹世华（香港） 曹雪涛 盛修贵 蒋国梁 程书钧 曾木圣  
曾益新 游伟程 詹启敏 赫 捷 管忠震 樊代明 樊 嘉 黎孟枫 颜光美 潘建基

## 组织委员会

主任委员：李建超 廖振尔 马 骏 彭望清 李升平 钱朝南 曾木圣

委 员：（按姓氏笔画排列）

元云飞	云径平	马 刚	邓务国	王辉云	邓燕明	申维玺	朱孝峰	刘孟忠	刘继红	孙晓非
吕 跃	刘万里	张 力	张 蓓	张为民	张兰军	张国君	张晓实	宋立兵	李安华	陈可欣
陈 明	陈忠平	陈敏山	邵建永	何裕隆	余伟平	周志伟	杨志刚	周芳坚	林丽珠	林桐榆
洪明晃	贾卫华	郭才旺	郭朱明	郭 翔	夏云飞	夏建川	高 嵩	符立梧	康铁邦	黄红兵
黄慧强	谢小明	谢 丹	覃惠英	曾维安	曹明溶	樊 卫	潘志忠			

## 秘书处（会务组）

秘 书 长：张秋艳 张晓薇 阮 继

副秘书长：覃惠英 周熙昕 黄金娟 曹蔚玮 胡 克 李志铭 王树森 刘 韬 邹本燕 干 峰  
何彩升

成 员：陈丽珍 陈志明 欧晓芳 陈 琼 林 铿 张志宏 甘可建 刘 玮 赵劲梅 余广彪  
陈 望 张 菊 林志祥 张庆龙 何仲廉 葛梦蝶 廖 爽 李仕心 钟 珺 罗宇栋  
黄中英 邹碧君 潘旭芝 张乐乐 各科秘书





# Organization

## Conference Chairmen

Yi-Xin Zeng Wei Zhang (USA)

## Executive Chairman

Rui-Hua Xu

## Academic Committee

Directors: Yi-Long Wu Er-Wei Song Peng Huang Rong-Cheng Luo Shu-Zhong Cui

Member:

Brian J. Druker (USA)	Carlos Arteaga (USA)	Glen N. Barber (USA)	Gregory Fuller (USA)		
Hui-Kuan Lin (USA)	Jill E. Wykosky (USA)	Jingwu Xie (USA)	Joe Chang (USA)		
Li Yan (USA)	Lynette Moore (USA)	Matti Nykter (Finland)	Nicholas Thatcher (UK)		
Olli Yli-Harja (Finland)	Thomas J. Lynch (USA)	Van Cutsem (Belgium)	Wei Zhang (USA)		
Webster Cavenee (USA)	Xiang-Xi Xu (USA)	Zhe-Sheng Chen (USA)			
Jian Ding	Yan-Qing Ding	Shi-Ying Yu	Jin-Ming Yu	De-Sen Wan	Ping Wang
Jian-Xiang Wang	Xiao-Yan Che	Han-Ping Shi	Yuan-Kai Shi	Tai-Xiang Lu	An-Li Shi
Tie-Hua Rong	You-Yong Lv	Jun Ren	Shi-Mei Zhuang	Zhi-Hua Liu	Qi Liu
Qiang Liu	Xin-Yuan Guan	Jing-Yan Tang	Yan-Qun Na	Li Sun	Yang-Qiu Li
En-Min Li	Ren-Jie Yang	Huan-Ming Yang	Hong Bu	Pei-Hong Wu	Hui-Yong Shen
Jin-Gang Song	Ning Zhang	Hao Zhang	Zhi-Yuan Zhang	Su-Zhan Zhang	Xiao-Peng Zhang
Dao-Pei Lu	Zhi-Nan Chen	Gui-Hua Chen	Zhi-Min Shao	Dong-Xin Lin	Hong-Sheng Lin
Jia-Fu Ji	Qing-Hua Zhou	Li-Min Zheng	Shi-Guang Zhao	Yang Ke	Lun-Xiu Qin
Xiao-Qing Jiang	Wen-Qi Jiang	Kai-Tai Yao	Shu-Kui Qin	Quan-Xing Ni	Guo-Quan Gao
Qian Tao (Hong Kong)	Wen-Lin Huang	Ya Cao	Shi-Hua Cao (Hong Kong)		Xue-Tao Cao
Xiu-Gui Sheng	Guo-Liang Jiang	Shu-Jun Cheng	Mu-Sheng Zeng	Yi-Xin Zeng	Wei-Cheng You
Qi-Min Zhan	Jie He	Zhong-Zhen Guan	Dai-Ming Fan	Jia Fan	Meng-Feng Li
Guang-Mei Yan	Jian-Ji Pan				

## Organizing Committee

Directors:

Jian-Chao Li Zhen-Er Liao Jun Ma Wang-Qing Peng Sheng-Ping Li Chao-Nan Qian Mu-Sheng Zeng

Members:

Yun-Fei Yuan	Jing-Ping Yun	Gang Ma	Wu-Guo Deng	Hui-Yun Wang	Yan-Ming Deng	Wei-Xi Shen
Xiao-Feng Zhu	Meng-Zhong Liu	Ji-Hong Liu	Xiao-Fei Sun	Yue Lv	Wan-Li Liu	Li Zhang
Bei Zhang	Wei-Min Zhang	Lan-Jun Zhang	Guo-Jun Zhang	Xiao-Shi Zhang	Li-Bing Song	An-Hua Li
Ke-Xin Chen	Ming Chen	Zhong-Ping Chen	Min-Shan Chen	Jian-Yong Shao	Yu-Long He	Wei-Ping Yu
Zhi-Wei Zhou	Zhi-Gang Yang	Fang-Jian Zhou	Li-Zhu Lin	Tong-Yu Lin	Ming-Huang Hong	
Wei-Hua Jia	Cai-Wang Guo	Zhu-Ming Guo	Xiang Guo	Yun-Fei Xia	Jian-Chuan Xia	Song Gao
Li-Wu Fu	Tie-Bang Kang	Hong-Bing Huang	Hui-Qiang Huang	Xiao-Ming Xie	Dan Xie	
Hui-Ying Qin	Wei-An Zeng	Ming-Rong Cao	Wei Fan	Zhi-Zhong Pan		

## Secretariat

Secretary-General:

Qiu-Yan Zhang Xiao-Wei Zhang Ji Ruan

Deputy Secretary-General:

Hui-Ying Qin Xin-Xi Zhou Jin-Juan Huang Wei-Wei Cao Ke Hu Zhi-Ming Li Shu-Sen Wang Tao Liu

Ben-Yan Zou Feng Gan Cai-Sheng He

Members:

Li-Zhen Chen	Zhi-Ming Chen	Xiao-Fang Ou	Qiong Chen	Keng Lin	Zhi-Hong Zhang	Ke-Jian Gan
Wei Liu	Jin-Mei Zhao	Guang-Biao Yu	Yun Chen	Ju Zhang	Zhi-Xiang Lin	Qing-Long Zhang
Zhong-Lian He	Mathilde Guerin	Shuang Liao	Shi-Xin Li	Jun Zhong	Yu-Dong Luo	Zhong-Ying Huang
Bi-Jun Zou	Xu-Zhi Pan	Le-Le Zhang				

Secretaries of the medical departments at SYSUCC



## 报名注册/Registration

时 间：2013年11月7日10:00–22:00  
2013年11月8日07:30–11:30

Time : 10:00–22:00 7 November  
07:30–11:30 8 November

地 点：酒店大堂

Location: Hotel lobby

流 程：办理报名、注册、交费，领取发票及大会资料，办理住宿

Process: Register and check in

## 食宿安排/Accommodation Arrangement

大会特别资助各位注册代表会议期间(11月8–9日)的午餐和晚餐

The lunches and the dinners during 8–9 November are sponsored by the conference organizers.

参会代表入住东方国际会议酒店

The representatives will stay at the Oriental International Convention Hotel.

大会闭幕后仍需住宿的代表，请务必提前24小时与酒店前台联系，有关费用自理

The representatives who want to stay longer after the conference need to contact the hotel reception before 9 November, and the additional fee will not be covered by the conference.

## 颁发学分/Credit Hour Issuing

时间：2013年11月9日 14:00–18:00

Time: 14:00–18:00, 9 November, 2013

地点：酒店大堂原报到处（凭注册发票）

Location: Hotel lobby

注：集体报名者以集体为单位领取



## 餐饮安排/Repast Arrangement

11月7日晚餐 -17:30-19:00 晚餐 (1号楼1楼西餐厅)
7 November Dinner, 17:30-19:00, Buffet dinner (Western Restaurant, Floor 1, Building 1)
11月8日早餐 -07:00-09:00-酒店自助早餐 (2号楼2楼多功能厅蓝区)
8 November Breakfast, 07:00-09:00, Buffet breakfast (Multi-purpose Hall, Floor 2, Building 2)
11月8日午餐 -12:10-13:30-卫星会 (1号楼1楼清和厅、4号楼1楼越秀华堂、2号楼2楼汕头厅)
8 November Lunch, 12:10-13:30, Satellite meeting lunch (Qinghe Room, Floor 1, Building 1; Yuexiu Grand Hall, Floor 1, Building 4; Shantou Room, Floor 2, Building 2)
11月8日晚餐 -18:00-20:00-自助晚餐 (2号楼2楼茂名厅)
8 November Dinner, 18:00-20:00, Buffet dinner (Maoming Room, Floor 2, Building 2)
11月9日早餐 -07:00-08:30-酒店自助早餐 (2号楼2楼多功能厅蓝区)
9 November Breakfast, 07:00-08:30, Buffet breakfast (Multi-purpose Hall, Floor 2, Building 2)
11月9日午餐 -12:10-13:30-卫星会(1号楼1楼清和厅、4号楼1楼越秀华堂)
9 November Lunch, 12:10-13:30, Satellite meeting lunch (Qinghe Room, Floor 1, Building 1; Yuexiu Grand Hall, Floor 1, Building 4)
11月9日晚餐 -18:20-20:00-自助晚餐 (2号楼2楼茂名厅)
9 November Dinner, 18:00-20:00, Buffet dinner (Maoming Room, Floor 2, Building 2)

## 会务组联系方式/Contact the Secretariat

1、会务组房号：白云国际会议中心·东方国际会议酒店1602房
联系电话：020-88800888转1602 联系人：小张：18898534201 小魏：18620877505
Room of the Secretariat: 1602 Tel: 020-88800888-1602 Dr. Zhang: 18898534201, Dr. Wei: 18620877505

## 温馨提示/Tips

1、胸卡：胸卡是参会代表的标识，请在参加所有会议活动和使用茶点时佩戴胸卡	
Please wear the name tag during the conference	
2、酒店电话：020-88800888	Hotel phone number: 020-88800888





# 会议议程 (一)

## Conference Agenda (I)

11月7日 报到注册 Nov 7th Registration & Reception		
11月8日 Nov 8th		
时间 Time	内容 Topic	讲者 Speaker
08:30-9:00	开幕式 Opening Ceremony 主持: 徐瑞华 教授 Hosted by: Prof. Rui-Hua Xu	
上午 大会 General Session		
主持: 曾益新 院士 万德森 教授 管忠震 教授 Hosted by: Prof. Yi-Xin Zeng, Prof. De-Sen Wan, and Prof. Zhong-Zhen Guan		
09:00-09:30	mRNA调控网络在卵巢癌和新治疗靶点中的应用 Master microRNA Regulatory Networks in Ovarian Cancer and New Therapeutic Targets	Prof. Wei Zhang (MD Anderson Cancer Center, USA) Wei Zhang 教授 (MD Anderson 癌症中心)
09:30-10:00	对癌症系统生物学的理解 Understanding Cancer Systems Biology	Ilya Shmulevich 教授 (美国基因组数据分析中心) Prof. Ilya Shmulevich (Genome Data Analysis Center, USA)
10:00-10:30	鼻咽癌放疗新进展 Recent Advances in Radiotherapy for Nasopharyngeal Cancer	Joseph Wee 教授 (新加坡国立癌症中心) Prof. Joseph Wee (National Cancer Center Singapore)
10:30-10:40	茶歇 Coffee Break	
10:40-11:10	乳腺癌保留乳房术后放射治疗的进展和挑战 Radiotherapy after Breast-Conserving Surgery in Breast Carcinoma: Advances and Challenges	于金明 院士 (山东省肿瘤医院) Prof. Jin-Ming Yu (Shandong Cancer Hospital)
11:10-11:40	细胞周期调控蛋白异常在肿瘤恶性表型形成中的作用及分子机制 Effect and its Molecular Mechanism of Cell Cycle Regulatory Proteins' Abnormality on the Formation of Malignant Phenotype of Tumors	詹启敏 院士 (中国医学科学院) Prof. Qi-Min Zhan (Chinese Academy of Medical Science)
11:40-12:10	中国的肺癌临床研究 Clinical Research of Lung Cancer in China	吴一龙 教授 (广东省人民医院) Prof. Yi-Long Wu (Guangdong General Hospital)
12:10-13:30	午餐 卫星会 (科技期刊发展论坛) Lunch & Satellite Meeting (Journal Development Session)	
下午 基础、转化分会场 Basic & Translational Medicine Session		
主持: 康铁邦 教授 符立梧 教授 朱孝峰 教授 Hosted by: Prof. Tie-Bang Kang, Prof. Li-Wu Fu, and Prof. Xiao-Feng Zhu		
13:30-13:55	Polycomb 2通过其SUMO E3连接酶活性来调控HIF-1 $\alpha$ 并促进肿瘤血管生成 Polycomb 2 Governs HIF-1 $\alpha$ to Potentiate Angiogenesis of Cancers by Its SUMO E3 Ligase Activity	陈国强 教授 (上海交通大学瑞金医院) Prof. Guo-Qiang Chen (Ruijin Hospital, Shanghai Jiao Tong University School of Medicine)
13:55-14:20	一种了解结肠直肠癌转移机制的组学方法 An Omics Strategy for Understanding the Mechanism of Colorectal Cancer Metastasis	丁彦青 教授 (南方医科大学) Prof. Yan-Qing Ding (Southern Medical University)
14:20-14:45	肿瘤干细胞代谢特性与药物干预 Metabolism of Cancer Stem Cells: Characteristics and Pharmaceutical Interventions	黄蓬 教授 (中山大学附属肿瘤医院) Prof. Peng Huang (Sun Yat-sen University Cancer Center)
14:45-15:10	癌症发病过程中细胞信号的表现遗传干扰 Epigenetic Disruption of Cell Signaling During Human Cancer Aethogenesis	陶谦 教授 (香港中文大学) Prof. Qian Tao (The Chinese University of Hong Kong)
15:10-15:35	靶向细胞周期激酶的肿瘤治疗基础 Therapeutic Basis of Targeted Cell Cycle Kinases for Tumors	刘强 教授 (中山大学附属肿瘤医院) Prof. Qiang Liu (Sun Yat-sen University Cancer Center)
15:35-15:45	讨论 Discussion	
15:45-16:00	茶歇 Coffee Break	



## 会议议程 (二) Conference Agenda (II)

主持: 郑利民教授 关新元教授 谢丹教授 Hosted by: Prof. Li-Min Zheng, Prof. Xin-Yuan Guan, and Prof. Dan Xie		
16:00-16:25	Warburg效应及其他 The Warburg Effect and Beyond	Zhimin Lu 教授 (MD Anderson癌症中心) Prof. Zhimin Lu (MD Anderson Cancer Center, USA)
16:25-16:50	抗血管生成靶向治疗的新观点 New Insights into Antiangiogenic Targeted Therapy	钱朝南 教授 (中山大学附属肿瘤医院) Prof. Chao-Nan Qian (Sun Yat-sen University Cancer Center)
16:50-17:15	逃逸miR-99a调控的致瘤性FGFR3-TACC3融合可能成为胶质母细胞瘤患者的有效治疗靶点 The Tumorigenic FGFR3-TACC3 Fusion Escapes miR-99a Regulation and May Serve as a Powerful Therapeutic Target for Glioblastoma Patients	Brittany C. Parker 教授 (MD Anderson癌症中心) Dr. Brittany C. Parker (MD Anderson Cancer Center)
17:15-17:40	整合基因组学与抗癌药物敏感性 Integrative Genomics and Anti-Cancer Drug Sensitivity	Yunguang Tong 教授 (UCLA医学院) Prof. Yunguang Tong (UCLA School of Medicine, USA)
17:40-18:00	讨 论 Discussion	
18:00-20:00	晚 餐 Dinner	
下午 临床分会场 Clinical Session		
主持: 戎铁华教授 罗荣城教授 李升平教授 张兰军教授 Hosted by: Prof. Tie-Hua Rong, Prof. Rong-Cheng Luo, Prof. Sheng-Ping Li, and Prof. Lan-Jun Zhang		
13:30-13:50	HEP2靶向对乳腺癌预测的研究 New perspective of HER2 targeting for breast cancer	宋尔卫 教授 (中山大学附属第二医院) Prof. Er-Wei Song (Second Affiliated Hospital of Sun Yat-sen University)
13:50-14:10	中国人肝细胞癌的特征和治疗选择 Features and Treatment Options of Chinese Hepatocellular Carcinoma	秦叔逵 教授 (中国人民解放军第八一医院) Prof. Shu-Kui Qin (Bayi Hospital of PLA)
14:10-14:30	肺癌的内科治疗 Medical Treatment of Lung Cancer	石远凯 教授 (中国医学科学院肿瘤医院) Prof. Yuan-Kai Shi (Cancer Institute & Hospital, Chinese Academy of Medical Science)
14:30-14:50	中国结直肠癌早诊早治筛查 Screening, Early Diagnosis & Treatment of Chinese Colorectal Carcinoma	张苏展 教授 (浙江大学附属第二医院) Prof. Su-Zhan Zhang (The 2nd Affiliated Hospital of Zhejiang University)
14:50-15:10	局部晚期肺癌基于分子分型和分子分期的“个体化”外科治疗进展 Advances in the Molecular Typing- and Molecular Staging-Based "Individual" Surgical Treatment of Locally Advanced Lung Carcinoma	周清华 教授 (天津医科大学) Prof. Qing-Hua Zhou (Tianjin Medical University)
15:10-15:30	胶质瘤治疗现状与思考 Treatment of Glioma: Current Status and More Considerations	陈忠平 教授 (中山大学附属肿瘤医院) Prof. Zhong-Ping Chen (Sun Yat-sen University Cancer Center)
15:30-15:45	讨 论 Discussion	
15:45-16:00	茶 歇 Coffee Break	
主持: 周志伟教授 邵建永教授 黄慧强教授 Hosted by: Prof. Zhi-Wei Zhou, Prof. Jian-Yong Shao, and Prof. Hui-Qiang Huang		
16:00-16:20	胃癌诊断治疗进展 Advances in the Diagnosis and Treatment of Gastric Carcinoma	季加孚 教授 (北京肿瘤医院) Prof. Jia-Fu Ji (Beijing Cancer Hospital)
16:20-16:40	乳腺癌肺转移机制的揭示及其临床应用 Mechanism for Lung Metastasis of Breast Carcinoma: Discovery and Clinical Application	邵志敏 教授 (复旦大学附属肿瘤医院) Prof. Zhi-Min Shao (Fudan University Shanghai Cancer Center)
16:40-17:00	精准腹腔热灌注化疗治疗胃肠癌的专家共识和临床路径 Expert Consensus and Clinical Pathway of Accurate Intraperitoneal Hyperthermic Perfusion Chemotherapy in Gastric Carcinoma	崔书中 教授 (广州医科大学肿瘤医院) Prof. Shu-Zhong Cui (Guangzhou Medical University Cancer Hospital)
17:00-17:20	肝癌微创治疗与多学科综合治疗 Minimal Invasive and Multi-Disciplinary Treatment of Hepatocellular Carcinoma	吴沛宏 教授 (中山大学附属肿瘤医院) Prof. Pei-Hong Wu (Sun Yat-sen University Cancer Center)
17:20-17:40	妇科恶性肿瘤的淋巴结转移问题 Issues on Lymph Node Metastasis of Gynecological Malignant Tumors	刘继红 教授 (中山大学附属肿瘤医院) Prof. Ji-Hong Liu (Sun Yat-sen University Cancer Center)
17:40-18:00	讨 论 Discussion	
18:00-20:00	晚 餐 Dinner	





## 会议议程 (三) Conference Agenda (III)

11月9日 Nov 9th		
上午 大会 General Session		
时间 Time	内容 Topic	讲者 Speaker
主持: 徐瑞华 教授 曾木圣 教授 傅剑华 教授 Hosted by: Prof. Rui-Hua Xu, Prof. Mu-Sheng Zeng, and Prof. Jian-Hua Fu		
08:30-09:00	安全低剂量水平的调幅电磁场对晚期肝细胞癌的靶向治疗 Targeted Treatment of Advanced Hepatocellular Carcinoma with Low and Safe Levels of Amplitude-Modulated Electromagnetic Fields	Boris Pasche 教授 (美国阿拉巴马大学伯明翰分校) Prof. Boris Pasche (The University of Alabama at Birmingham, USA)
09:00-09:30	转移性结肠癌的个体化治疗 Personalized Therapy in mCRC	Sabine Tejpar 教授 (比利时科学研究基金会) Prof. Sabine Tejpar (Fund for Scientific Research-Flanders, Belgium)
09:30-10:00	大数据、机器学习和癌症 Big Data, Machine Learning, and Cancer	Olli Yli-Harja 教授 (坦佩雷理工大学) Prof. Olli Yli-Harja (Tampere University of Technology, Finland)
10:00-10:10	茶 歇 Coffee Break	
10:10-10:40	肿瘤的质子和重离子放疗 Proton and Heavy-Ion Radiotherapy in Tumors	蒋国梁 教授 (复旦大学附属肿瘤医院) Prof. Guo-Liang Jiang (Fudan University Shanghai Cancer Center)
10:40-11:10	对EGFR驱动的胶质母细胞瘤肿瘤发生的新观点以及对胶质母细胞瘤干细胞的研究 New Insights of EGFR-Driven Glioblastoma Tumorigenesis and Characterization of Glioblastoma Stem Cells	Shi-Yuan Cheng 教授 (西北大学Feinberg医学院) Prof. Shi-Yuan Cheng (Northwestern University Feinberg, USA)
11:10-11:40	miRNA对肿瘤细胞中关键信号通路的修饰和调控 Modification and Regulation of Key Signaling Pathways by miRNA in Tumor Cells	黎孟枫 教授 (中山大学医学院) Prof. Meng-Feng Li (Zhongshan School of Medicine, Sun Yat-sen University)
11:40-12:00	2013 USCACA-NFCR颁奖典礼 2013 USCACA-NFCR Award Ceremony 优秀Poster颁奖	
12:00-13:30	午餐 卫星会 Lunch & Satellite Meeting	
下午 临床分会场 Clinical Session		
主持: 刘孟忠 教授 林桐榆 教授 郭朱明 教授 吕跃 教授 Hosted by: Prof. Meng-Zhong Liu, Prof. Tong-Yu Lin, Prof. Zhu-Ming Guo, and Prof. Yue Lv		
13:30-13:55	基于现代影像技术的鼻咽癌综合治疗研究与应用 Studies and Applications of the Comprehensive Treatment in Nasopharyngeal Carcinoma Based on Modern Imaging Techniques	马 骏 教授 (中山大学附属肿瘤医院) Prof. Jun Ma (Sun Yat-sen University Cancer Center)
13:55-14:20	提高结直肠癌肝转移切除率的策略 Strategies of Improving the Resection Rate of Liver Metastasis in Colorectal Cancer	潘志忠 教授 (中山大学附属肿瘤医院) Prof. Zhi-Zhong Pan (Sun Yat-sen University Cancer Center)
14:20-14:45	NK/T细胞淋巴瘤治疗诊断新进展 Recent Advances in Diagnosis and Treatment of NK/T-Cell Lymphoma	李晔雄 教授 (中国医学科学院肿瘤医院) Prof. Ye-Xiong Li (Cancer Institute & Hospital, Chinese Academy of Medical Science)
14:45-15:10	肝癌MDT团队的建立与多学科联合治疗策略 Setting Up of a Multi-Disciplinary Team and Multi-Disciplinary Therapeutic Strategy in Hepatocellular Carcinoma	陈敏山 教授 (中山大学附属肿瘤医院) Prof. Min-Shan Chen (Sun Yat-sen University Cancer Center)
15:10-15:35	沿用一个世纪的旧范式的转变: 来自多倍体巨大癌细胞的启示 A Century Old Paradigm Shift: a Tale from Polyploid Giant Cancer Cells	Jinsong Liu 教授 (MD Anderson癌症中心) Prof. Jinsong Liu (MD Anderson Cancer Center, USA)
15:35-15:45	讨 论 Discussion	
15:45-16:00	茶 歇 Coffee Break	



## 会议议程 (四) Conference Agenda (IV)

主持: 夏建川教授 洪明晃教授 谢小明教授 Hosted by: Prof. Prof. Jian-Chuan Xia, Prof. Ming-Huang Hong, and Prof. Xiao-Ming Xie		
16:00-16:25	弥漫型大B细胞淋巴瘤的临床研究现状和发展方向 Clinical Studies of Diffuse Large B-Cell Lymphoma: Current Status and Future Directions	姜文奇 教授 (中山大学附属肿瘤医院) Prof. Wen-Qi Jiang (Sun Yat-sen University Cancer Center)
16:25-16:50	急性髓细胞白血病 (AML) 治疗最新国际临床解读 Interpretation of the Most Recent International Guideline for the Treatment of Acute Myeloid Leukemia (AML)	马 军 教授 (哈尔滨血液病肿瘤研究所) Prof. Jun Ma (Harbin Institute of Hematology and Tumor)
16:50-17:15	泌尿生殖系肿瘤诊疗进展 Advances in Diagnosis and Treatment of Genitourinary Tumors	周芳坚 教授 (中山大学附属肿瘤医院) Prof. Fang-Jian Zhou (Sun Yat-sen University Cancer Center)
17:15-17:40	半相合移植是否适用于所有患者? ——北京经验 Has the Time for Haploidentical Transplant Arrived for All Patients? The Beijing Experience	黄晓军 教授 (北京大学人民医院) Prof. Xiao-Jun Huang (Peking University People's Hospital)
17:40-17:50	讨 论 Discussion	
18:00-20:00	晚 餐 Dinner	
下午基础、转化、临床研发分会场 Basic, Translational and Clinical Research Session		
主持: Li Yan 教授 张力 教授 Hosted by: Prof. Li Yan and Prof. Li Zhang		
<b>第1节 即将面世的抗癌新药: 肿瘤免疫治疗 (主持: Dr. George Wilding, 威斯康辛癌症中心教授、前任主任)</b> <b>Seminar 1. New Anti-Cancer Drugs in the Horizon: Cancer Immunotherapy</b> (Chair: Dr. George Wilding, Professor and former Director of Wisconsin Comprehensive Cancer Center)		
13:30-14:10	肿瘤抗体治疗的发展 The Evolution of Antibody Cancer Therapies	Helen Chen 教授, 美国NCI/CTEP副主席 Prof. Helen Chen, Associate Chief, US NCI/CTEP
14:10-14:40	肿瘤治疗中的抗PD1治疗 Anti-PD1 in Cancer Treatment	Li Yan 教授, 默克肿瘤部执行总监 Prof. Li Yan, Executive Director of Oncology, Merck
14:40-15:00	小组讨论+问答 Panel Discussion + Q&A	专家名单: Li Yan 教授, Helen Chen 教授 Panelists: Prof. Li Yan, Helen Chen
<b>第2节 即将面世的抗癌新药: 抗体-药物偶联剂和第三代激酶抑制剂 (主持: Michael Shi, 诺华制药高级总监)</b> <b>Seminar 2. New Anti-Cancer Drugs in the Horizon: Antibody-Frug Conjugates (ADCs) and Third Generation Kinase Inhibitors</b> (Chair: Michael Shi, Senior Director, Novartis)		
15:00-15:25	一种第三代非可逆性突变特异性的EGFR抑制剂 A Third Generation Irreversible, Mutation-Specific EGFR Inhibitor	Xiao Xu, AceaBio主席兼首席执行官 Xiao Xu, President and CEO of AceaBio
15:25-15:50	贝伦妥单抗-维多汀抗体-药物偶联剂研发的个案研究 A Case Study of ADC — Development of Brentuximab Vedotin	Wenru Song, Millennium/Takeda高级总监 Wenru Song, Senior Director, Millennium/Takeda
15:50-16:10	小组讨论+问答 Panel Discussion + Q&A	专家名单: Xiao Xu 教授, Wenru Song 教授, Jianmin Fang 教授 Panelists: Prof. Xiao Xu, Prof. Wenru Song, Prof. Jianmin Fang
16:10-16:30	茶 歇 Coffee Break	
<b>第3节 中国肿瘤药物研发中的管理和临床问题 (主持: Li Xu, Zhimin Yang)</b> <b>Seminar 3. Regulatory and Clinical Considerations in Oncology Drug Development in China (Co-Chairs: Li Xu, Zhimin Yang)</b>		
16:30-16:50	肿瘤药物临床研发中的绿色通道和生物标志物的应用 Green Channel Process and Consideration of Biomarker Applications in Clinical Development of Oncology Drugs	Zhimin Yang, 国家食品药品监督管理总局 Zhimin Yang, CFDA
16:50-17:10	中国乳腺癌筛查项目的评估 Assessment of Breast Cancer Screening Program in China	陈可欣 教授 (天津医科大学附属肿瘤医院) Ke-Xin Chen (Tianjin Medical University Cancer Institute and Hospital)
17:10-17:30	生物标志物驱动的试验在实施中的实际问题 Practical Considerations in Conducting Biomarker-Driven Trials	Sven Tang, inVentiv肿瘤医学总监 Sven Tang, Oncology Medical Director, inVentiv
17:30-17:50	小组讨论+问答 Panel discussion + Q&A	专家名单还包括美国FDA的Al Deisseroth, 杨森公司的Roger Luo, 以及诺华公司的Michael Shi Panelists also include Al Deisseroth from US FDA, Roger Luo from J&J, Michael Shi from Novartis
18:20-20:00	晚 餐 Dinner	





曾益新

曾益新，中国科学院院士、中国科学院（原第三世界科学院）院士、国际欧亚科学院院士。北京协和医学院校长、中山大学肿瘤防治中心主任、华南肿瘤学国家重点实验室主任。

曾益新院士的研究重点是恶性肿瘤的发病机理及肿瘤的生物治疗，尤其在在我国南方高发的鼻咽癌的发病机理方面取得突出成就。其研究工作曾获评“中国医药卫生十大科技新闻”和“中国高等学校十大科技进展”。作为第一责任人获得省部级一等奖三项，国家自然科学基金二等奖一项。曾获评“中国十大优秀青年科学家奖”、“何梁何利科技进步奖”、“广东省科技突出贡献奖”及“中国高校优秀教师”、“卫生部突出贡献中青年专家”、“国务院特殊津贴专家”、“广东省十大创新人物”等荣誉称号。曾入选“新世纪百千万人才工程”首批国家级人选。2010年获颁瑞典卡罗琳斯卡医学院为其200周年校庆颁出的第一枚大银质奖章。获聘卡罗琳斯卡医学院外籍兼职教授、香港中文大学临床荣誉教授、澳门科技大学荣誉教授。

1997年至今，曾益新院士先后获得CMB基金、国家杰出青年基金、美国NIH R01基金等科研项目的支持，担任863重大专项“重大疾病的分子分型和个体化诊疗”的总体专家组组长、973项目“病毒致瘤的分子机理研究”的首席专家。在学术期刊上共发表论文300余篇，其中在SCI收录刊物上发表220余篇。

担任《癌症》杂志主编、卫生部统编研究生教材《肿瘤学》主编、*Journal of Biological Chemistry*、*Cancer Biology and Therapy*、*Cell Cycle*、*Journal of Translational Medicine*等杂志的编委。曾任WHO国际癌症研究机构“肿瘤分子分型工作委员会”主席、国际EB病毒与相关疾病协会理事长。现兼任中国抗癌协会副理事长、广东省抗癌协会理事长、广东省医学会副会长、中国青年科协副会长、广东省科协副主席、广东省青联副主席、广东省青科协会会长。





Wei Zhang, Ph.D.  
Professor and director  
Cancer Genomics Core Lab  
M.D. Anderson Cancer Center

#### Education and working experience

1994-present Faculty MD. Anderson Cancer Center, Houston, Texas  
1999-present Director Cancer Genomics Core Lab, MDACC  
2006-present Project Director National Foundation for Cancer Research, US  
2010-2013 President US Chinese Anti-Cancer Association

Dr. Zhang received his BS degree in biochemistry from Beijing University in 1985. He came to the graduate school in the US under the CUSBEA program in 1986 and received his PhD degree in molecular biology from The University of Texas Graduate School of Biomedical Sciences in Houston, Texas. Dr. Zhang is currently a Professor in Pathology and Cancer Biology in the Department of Pathology and at The University of Texas Graduate School of Biomedical Sciences. Dr. Zhang has published more than 250 peer-reviewed papers, 7 invited articles, and 21 book chapters. Dr. Zhang is a holder of 2 US patents. Dr. Zhang co-edited two books (*Statistical and Computational Approaches to Genomics*, 1st and 2nd editions, and *Genomic and Molecular Neuro-Oncology*, translated into Chinese) and co-authored one book (*Microarray Quality Control*). Dr. Zhang is a co-director of one of seven Genome Data Analysis Centers (GDAC) under the Cancer Genome Atlas (TCGA) project funded by NCI. Since 1997, Dr. Zhang has been actively involved in cancer genomics and systems biology research.



徐瑞华

徐瑞华，教授、博士生导师，中山大学肿瘤防治中心副主任、副院长，2007年教育部新世纪优秀人才。广东省抗癌协会副理事长兼秘书长，中国抗癌协会临床肿瘤学协作中心委员会（CSCO）常务委员，中国抗癌协会大肠癌专业委员会常务委员，广东省抗癌协会胃癌专业委员会副主任委员，广东省抗癌协会大肠癌专业委员会常务委员，国家食品药品监督管理局（SFDA）药物审评咨询专家，美国临床肿瘤学会（ASCO）会员、美国癌症研究协会（AACR）会员。《癌症》、《临床肿瘤学杂志》、《肿瘤研究与临床》编委，*Cancer*、*Chemotherapy*、*BMC Cancer* 等杂志审稿专家。

长期从事肿瘤内科的临床工作及抗癌药物（化疗药物及分子靶向治疗药物）研究。在消化道肿瘤（肠癌、胃癌、食道癌、胰腺癌、肝癌）的综合治疗及研究有较深的造诣。2002年前往美国德州安德森（M.D. Anderson）癌症中心工作，被聘为客座副教授，2005年回国。负责执笔撰写中国版《NCCN结肠癌临床指导原则》和《NCCN直肠癌临床指导原则》临床共识，参与撰写中国版《NCCN胃癌临床指导原则》及《NCCN胰腺癌临床指导原则》临床共识，负责、参与了多项国际及国内抗肿瘤新药的临床试验。

在国内外重要期刊共发表文章70余篇，近年来有多篇文章发表在国际上重要的学术期刊上，如 *Journal of National Cancer Institute*, *Journal of Cell Biology*, *Cancer Research*, *Oncogene*, *Leukemia*, *Cancer* 等负责及参与了近20余项国家、部省级的科研课题，并参加了一项美国国立卫生院的重大研究。





Ilya Shmulevich

Ilya Shmulevich, Ph.D.

Professor, The Institute for Systems Biology

Ilya Shmulevich received his Ph.D. in Electrical and Computer Engineering from Purdue University, West Lafayette, IN, in 1997. From 1997-1998, he was a postdoctoral researcher at the Nijmegen Institute for Cognition and Information at the University of Nijmegen and National Research Institute for Mathematics and Computer Science at the University of Amsterdam in The Netherlands, where he studied computational models of music perception and recognition. In 1998-2000, he worked as a senior researcher at the Tampere International Center for Signal Processing at the Signal Processing Laboratory in Tampere University of Technology, Tampere, Finland. From 2001-2005, he was an Assistant Professor at the Cancer Genomics Laboratory in the Department of Pathology at The University of Texas M. D. Anderson Cancer Center and an Adjunct Professor in the Department of Statistics in Rice University. Presently, he is a Professor at The Institute for Systems Biology, where he directs a Genome Data Analysis Center that is part of The Cancer Genome Atlas (TCGA) project. He is an Affiliate Professor in the Departments of Bioengineering and Electrical Engineering at the University of Washington, Department of Signal Processing in Tampere University of Technology, Finland, and Department of Electronic and Electrical Engineering in Strathclyde University, Glasgow, UK. He is an Associate Editor of EURASIP Journal on Bioinformatics and Systems Biology and a Senior Member of the IEEE. His research interests include systems biology, nonlinear signal and image processing, and computational learning theory.



Joseph Wee

Dr Joseph Wee is a Senior Consultant in the Radiation Oncology Division as well as Chairman, Medical Board at the National Cancer Centre, Singapore, and an adjunct Associate Professor at the Duke-NUS Graduate Medical School. He graduated MBBS from the National University of Singapore and obtained his Fellowship of the Royal College of Radiologists in Clinical Oncology in 1991. He was elected Fellow of The Academy of Medicine of Singapore in 1995. His primary research interest is in Nasopharyngeal Cancer and Intensity Modulated Radiation Therapy, and he has published several papers in this area. He has also received several grants for research in NPC and was instrumental in setting up IMRT for NPC in Singapore. In 2009, he received the Singapore National Medical Research Council, Clinician Scientist Award (Senior Investigator) to perform clinical trials in NPC.





于金明

于金明，中国工程院院士，放射学博士，中共山东省委委员，山东省医学科学院名誉院长（正厅级）、山东省肿瘤医院院长，博士生导师，中国抗癌协会副理事长，中华医学会放射肿瘤学专业委员会前任主任委员和中国抗癌协会放疗专业委员会主任委员，山东省抗癌协会理事长，中央保健会诊专家和中央联系的高级专家，现任《中华肿瘤防治杂志》和《中华放射肿瘤学杂志》等多家杂志的主编或副主编。

1988年至1993年在美国弗吉尼亚大学和哈佛大学从事肿瘤放射治疗研究，近年来带领他的团队创造性地率先开展影像引导的放疗、生物靶向放疗等多项新技术，是我国现阶段开创性地开展肿瘤精确放疗新技术、新方法的开拓者之一。他的研究成果修改了美国、欧洲、加拿大和中国等多个国家的肿瘤临床治疗指南和规范，其率领的团队被山东省委、省政府评为“山东省十大优秀创新团队”，并记集体一等奖。

他先后获得国家和省部级科技奖12项，其中以首位完成人获得国家科技进步二等奖2项、省科技进步一等奖3项，2010年荣获山东省科学技术最高奖。他主持和参与国家“863”、“十一五”、“十二五”和国家自然科学基金等项目20余项。出版或参编专著20余部，以第一或通讯作者在国内杂志发表学术论文600余篇，其中SCI收录100余篇，被《新英格兰医学杂志》和《柳叶刀》等国外期刊引用500余次。多次应邀到美国哈佛大学、斯坦福大学等国际著名大学和医疗机构进行学术讲座，多次应邀到美国肿瘤年会（ASCO）和美国放射肿瘤学年会（ASTRO）等欧美国际学术大会做主题报告。近年来先后培养了硕士、博士和博士后100多名。

他先后荣获山东省劳动模范、全国卫生系统劳动模范、全国五一劳动奖章和全国劳动模范等称号。先后被评为山东省十大中青年科技专家、山东省十佳优秀专业技术人员、山东省和卫生部有突出贡献中青年专家、山东省委、省政府首批“泰山学者”特聘专家、山东省首批“泰山学者攀登计划”专家、全国优秀留学归国人员和国家人事部特聘专家，是第十届、十二届全国人大代表和中共十七大党代表。



詹启敏

詹启敏，中国工程院院士、中国医学科学院副院长、北京协和医学院副校长、分子肿瘤学国家重点实验室主任、国家863高技术计划医药生物技术专题专家组组长、教育部长江学者、国家杰出青年基金获得者、国家基金委创新群体首席专家、新世纪百千万人才工程国家级人选、国家973重大基础研究项目（肿瘤转移）首席科学家。中国微循环学会理事长、中国抗癌协会副理事长。担任*J Biol Chem*（美国）、*Cancer Biol and Ther*（美国）、*Molecular Oncology*（芬兰）等国际学术杂志的编委，担任《科学通报》、《中华肿瘤》、《转化医学》杂志副主编。

长期致力于肿瘤分子生物学和转化医学研究，在细胞周期调控、基因组稳定性和细胞癌变机制研究中取得原创性和系统性成果。至今，已在国际医学生物学杂志上发表SCI论文140多篇。发表论文的SCI引用超过11,000次。





吴一龙

吴一龙，教授，广东省人民医院副院长、广东省肺癌研究所所长；中国抗癌协会常务理事、CSCO候任主任委员、CSLC前任主任委员、C-TONG主席、世界华人胸外科学会会长IASCL国际分期委员会委员、ASCO国际事务部委员，国内外多家中英文杂志主编、副主编、编委。主持和参与了多项国内外肺癌多中心随机对照研究。领导组织完成了我国肺癌领域多个共识和临床指引。SCI文章60余篇，作为主编、副主编、编委出版了16本著作，专利6项，荣获科技进步奖9项。



陈国强

陈国强，医学博士、教授，上海交通大学医学院院长，上海交通大学副校长，细胞分化与凋亡教育部重点实验室主任。1997年获得国家杰出青年科学基金，并在2002年担任交通大学医学院病理生理学教研室主任，独立带领他的团队，致力于急性髓系白血病（AML）和肿瘤的病理生理学研究，取得系列系统性和创新性研究成果，如在发现低氧能够诱导多种类型的AML细胞分化的基础上，进一步报道低氧调控的低氧诱导因子-1 $\alpha$ （HIF-1 $\alpha$ ）蛋白直接参与白血病细胞分化，并揭示HIF-1通过与两个造血相关的蛋白质C/EBP $\alpha$ 和Runx1直接相互作用，有效增加这些蛋白的转录活性，进而诱导白血病细胞分化；利用“发现抗白血病活性化合物→探索相应的药物靶标→揭示白血病细胞命运决定的分子机制”的策略，发现了结合过氧化物还原酶（Prx）家族成员Prx I/II蛋白的天然化合物——腺花素，并阐明腺花素通过特异结合和抑制Prx I/II的抗氧化活性，诱导细胞分化和清除白血病祖细胞，有效延长白血病小鼠生存时间，明确了Prx I/II作为治疗白血病的新药物靶点的重要性。*Angew Chem Int Edit*杂志将该成果作为识别药物靶标的十大案例之一进行综述，并入选2012年度“中国科学十大进展”。迄今，陈国强在*Nature Cell Biol*、*Blood*、*Leukemia*、*Nature Communication*、*Nature Cell Biol*等发表110余篇学术论文，被他人引用4000多次，并先后作为第一完成人获得国家自然科学二等奖、中华医学科技一等奖、上海自然科学一等奖、上海科技进步一等奖等奖项，并获全国优秀博士学位论文指导教师、全国劳动模范、上海市劳动模范、上海十大杰出青年等荣誉称号。





丁彦青

Yanqing Ding is a professor, chief physician and doctoral advisor. He is one of the famous experts in tumor pathology in China. He has been a member of the subject evaluation group of the academic degree committee of the State Council and awarded the special allowance by the State Council. He was also granted as provincial and national outstanding university teacher award and excellent scientific worker of CAST (China Association of Science & Technology). He was gainer of "Ding Ying Science and Technology Prize of Guangdong Province" and PLA Education Gold Award. He is evaluation expert of Natural Science Foundation of China, and Scientific Research Foundation for Returned Overseas Chinese Scholars.

Prof. Ding was appointed as the director of department of pathology, school of basic medical sciences & Nanfang hospital, southern medical university. He is also the director of Guangdong provincial key laboratory of Molecular Tumor Pathology, chairman of Guangdong Pathologist Association, vice chairman of Chinese Pathologist Association, Committee of Chinese Pathologist and Society of Tumor Metastasis of China Anti-Cancer Association. He is a person in charge of National Excellent Courses. He also holds the journal *Chinese Journal of Diagnostic Pathology* as Associate Editor-in-Chief and was invited as Executive Members or Board Members of the Editorial Board, such as *Chinese Journal of Pathology*, *Chinese Journal of Neuromedicine*, *Chinese Journal of Lung Cancer*, *Modern Digestion & Intervention*, and *Journal of Southern Medical University*. He was invited review of several international journals, such as *Lancet*, *Am J Nephrology*, *J clinical Pathology*, *J Translation Medicine* and *Cell Biology International*.

In recent years, he has presided 26 national or provincial projects, including 863 Project, 973 Project and Natural Science Foundation of China. He has published more than 200 papers. Among them, 62 papers have been included in SCI journal, such as *N Eng J Med*, *Gastroenterology*, *Gut*, *Cell Reserch*, *Clin Cancer Res*, *J Path*, *J Proteomics Research*, etc. He has been awarded 7 nationaegrees.l and provincial prizes for progress in science and technology. So far, he has trained and recruited more than 136 graduates for both the Masters and Ph.D. d



黄蓬

黄蓬，教授，博士，中山大学肿瘤防治中心肿瘤学、分子医学和药物博士生导师。1990年毕业于美国德州大学生物医学研究生院，获得肿瘤药理学专业博士学位。美国德州大学M.D. Anderson Cancer Center终身教授，2008年教育部长江学者讲座教授，2010年国家“千人计划”特聘专家，2011年广东省创新领军人才，主要研究方向为肿瘤代谢调控,肿瘤细胞线粒体功能异常,及抗癌药物研发。





陶 谦

陶谦，香港中文大学肿瘤学系终身教授，国际表观遗传学会 (The Epigenetics Society) 副主席。国家杰青B类获得者，香港中文大学青年学者优秀成果奖获得者。主要研究方向肿瘤表观遗传学 (Cancer epigenetics)，包括筛选和鉴定受启动子CpG甲基化沉默的新抑癌基因及其在肿瘤发生中的功能和机理研究，肿瘤表观遗传分子标志物和治疗研究。

1995年毕业于香港大学获博士学位；1995-1999年在约翰霍普金斯大学医学院 (Johns Hopkins School of Medicine) Sidney Kimmel 癌症中心从事博士后研究；1999年被聘为约翰霍普金斯大学医学院肿瘤学系助理教授及约翰霍普金斯大学医学院新加坡研究中心肿瘤表观遗传学实验室首席研究员；2001年及2004年相继被聘为新加坡国立大学及香港中文大学副教授；2008年被聘为香港中文大学教授。担任英国MRC, Wellcome Trust, 新加坡BMRC, 香港RGC及中国NSFC终审海外评委。为国际专业期刊*Lancet*, *Blood*, *Oncogene*, *HMG*, *Cancer Res*, *PLoS Genetics*等51种杂志的特约审稿人, *PLoS ONE*及《癌症》杂志编委。应邀在国际、国内学术会议上做大会发言、特邀报告或分会主席80多次。作为PI承担A\*STAR Singapore、Michael Kadoorie Cancer Genetics基金、Hong Kong RGC、NSFC课题及基金项目多项。已发表SCI论文120多篇，包括国际重点杂志*PNAS*, *Lancet*, *JCO*, *Blood*, *HMG*, *Gastroenterol*, *Hepatology*, *Cancer Res*, *Oncogene*及*JV*等文章多篇。编写全国研究生教材《肿瘤学》2012第三版“肿瘤表观遗传学”一章。



刘 强

刘强，南京大学学士，美国理学和临床医学双博士，纽约西奈山医学中心临床住院医生，哈佛大学医学院博士后。2006年回国，任中山大学肿瘤防中心教授。是973首席科学家，国家杰出青年基金获得者，“百千万人才”工程国家级人选，美国医学及生物工程院 (AIMBE) Fellow及美国中华医学会 (CMB) 杰出教授，获得中国抗癌协会科技奖二等奖。在*JCO*, *PNAS*, *Blood*, *Cancer Res*等发表论文50篇。





Zhimin Lu

Zhimin Lu, M.D., Ph.D

Professor, Departments of Neuro-Oncology and Molecular and Cellular Oncology  
The University of Texas MD Anderson Cancer Center

Dr. Zhimin Lu is a professor of neuro-oncology and molecular and cellular oncology at The University of Texas MD Anderson Cancer Center. He is an associate editor of the Chinese Journal of Cancer and a member of the editorial boards of more than 10 journals, including *Cell Research*, *The Journal of Biological Chemistry*, and *Neuro-Oncology*. He received the Peter Steck Memorial Young Investigator Award in 2008. He earned his Ph.D. at The City University of New York and completed his postdoctoral training in Dr. Tony Hunter's laboratory at the Salk Institute for Biological Studies.

Dr. Lu's work is aimed at delineating the mechanisms of cellular signaling regulation in cancer cell metabolism, proliferation, migration, and metastasis. His laboratory focuses on three areas: how cancer advances by altering cancer cell metabolism; how cancer cells migrate, invade, and metastasize; and how cancer progresses via enhanced cell survival. His work on merged regulation of cancer metabolism and cell cycle progression by PKM2-dependent epigenetic regulation of gene expression was highlighted as one of the signaling breakthroughs in 2012 by *Science Signaling*. Dr. Lu has published more than 60 research articles in top-tier journals, including more than 10 research articles in *Nature*, *Cell*, *Cancer Cell*, *Nature Cell Biology*, and *Molecular Cell*.



钱朝南

钱朝南，1999在中山医科大学获医学博士学位。2000-2003年分别在美国德州大学 MD Anderson Cancer Center 和 Van Andel Research Institute 接受博士后培训。曾兼职新加坡国立癌症中心转化研究实验室副主任。2007年6月，作为中山大学百人计划引进人才在中山大学肿瘤防治中心鼻咽科担任研究员、博士生导师。2008年被中国卫生部聘为“健康中国2020”战略研究专家。2008年开始担任中山大学肿瘤防治中心院长助理。2009年底开始担任《癌症》杂志(*Chinese Journal of Cancer*) 副主编。

长期从事肿瘤转移、肿瘤血管生成的研究。主持国家自然科学基金重点项目、国家自然科学基金面上项目、卫生部重大专项分题、863项目分题等。在SCI收录的杂志发表论文60余篇，为30多个国际期刊担任审稿人。是多个国家级科研基金委的评审专家，包括中国自然科学基金委、英国 The Medical Research Council、新西兰 Foundation of Health Research Council, 等。





Brittany C. Parker

Brittany C. Parker is currently a PhD candidate in the lab of Wei Zhang, PhD at MD Anderson Cancer Center in Houston, TX, USA. She attended the University of California, Irvine for her Bachelors of Science degree in biology. After graduation, she performed research in the Retinal Disease department at the pharmaceutical company Allergan, Inc. located in Irvine, California. Brittany began her PhD at MD Anderson Cancer Center in 2009, where she joined the FGFR3-TACC3 fusion project that was recently discovered by her lab via deep RNA sequencing. The fusion was found to escape microRNA regulation and to be highly tumorigenic both *in vitro* and *in vivo*. With joint efforts from MD Anderson, Finland, and China, her work was published this past February in *The Journal of Clinical Investigation*. She also coauthored a review article on methods to discovery fusion genes published in *Cancer Letters*. Brittany has earned over a dozen awards while in graduate school, namely for her academic achievements, community service, and research efforts, including the Caroline Ross Endowment Fund Fellowship in Brain Cancer Research, First place oral platform presentation at MD Anderson Cancer Center Trainee Research Day, Tzu-Chi Foundation Scholarship for Excellence, Dee S and Patrica Osbourne Endowed scholarship in the neurosciences, to name a few. Brittany is now focused on identifying effective strategies to target the fusion in fusion-positive patients by using both *in vitro* and mouse modeling techniques, as well as identify the causative mechanism leading to fusion formation.



Yunguang Tong

Dr. Yunguang Tong received his Ph.D. degree in tumor pharmacology from the Shanghai Institute of Material Medica in 2004. He had his postdoctoral training in cancer biology, molecular endocrinology and bioinformatics at Cedars-Sinai Medical Center and UCLA School of Medicine during 2005-2010. Afterwards, he was appointed as a research scientist and assistant professor of medicine at UCLA School of Medicine.

Dr. Tong was a council member of Associate Council Member for America Association for Cancer Research (AACR) in 2005-2008. He is an ad-hoc reviewer for journals such as *Plos One*, *Acta Pharmacologica Sinica (APS)*, *International Journal of Cancer* and *Chinese Journal of Cancer*. He is also an associate editor for *Chinese Journal of Cancer*. One of his interests is to use integrative genomic approaches in identifying biomarkers for cancer treatment. Dr. Tong has published more than 20 papers in peer-reviewed journals such as *Oncogene*, *Clinical Cancer Research*, *Molecular Pharmacology*, *European Journal of Pharmacology* and *Molecular Endocrinology*.

Dr. Tong received several awards from AACR and Endocrine Society and was the recipient of Malaniak Award for excellence in postdoctoral research in 2008. He received Howard Temin Pathway to Independence Award from NCI in 2010. His research is currently supported by a R00 grant from NCI and a research grant from US Chinese Anti-Cancer Association.





宋尔卫

宋尔卫是教育部长江学者特聘教授，美国中华医学基金会（CMB）杰出教授。曾获国家重大科学研究计划（任首席科学家）、国家杰出青年基金及国家自然重点项目等资助。发表SCI收录论文71篇，其中第一作者和通讯作者42篇，总影响因子达450分。主要从事非编码RNA调控乳腺癌发病机制及应用研究，首次在整体动物模型应用RNA干扰治疗疾病并揭示微分子RNA调控乳腺癌的干细胞特性，成果曾被评为“2003年度全球十大科技突破”和“2008年中国高校十大科技进展”。



秦叔逵

秦叔逵教授，主任医师、教授和博士生导师，现任解放军八一医院副院长、全军肿瘤中心主任兼国家药物临床试验机构主任。长期从事肿瘤内科临床和科研工作，擅长消化系统肿瘤（特别是肝癌）的诊治和研究。

担任亚洲临床肿瘤学联盟(FACO)主席，国际肿瘤免疫学会（SITC）理事，亚洲临床肿瘤学会（ACOS）常务理事，中国临床肿瘤学会（CSCO）基金会理事长，国家卫生部肿瘤规范化诊治专家委员会委员、肝癌、胃肠间质瘤和癌痛专家组组长，中国医师协会肿瘤医师考核委员会主任，中华医学会肿瘤学专委会委员，中国抗癌协会（CACA）全国理事和癌症康复与姑息治疗委员会副主委，解放军全军医科委理事兼肿瘤专委会常委，南京军区医科委常务理事兼肿瘤专委会主委等一系列学术职务，系国家统计源期刊《临床肿瘤学杂志》和SCI核心杂志*Oncologist*（中文版）的主编。多年来，曾发表科技论文510余篇，编写专著50部；获得国家科技进步二等奖1项，省部级科技成果一等奖4项、二等奖3项、三等奖9项及四等奖2项；享受国务院特殊津贴和军队特殊津贴。





石远凯

石远凯，教授，博士生导师，现任中国医学科学院肿瘤医院副院长、国家抗肿瘤药物临床研究机构副主任、抗肿瘤分子靶向药物临床研究北京市重点实验室主任主任、中国医师协会肿瘤医师分会会长、中国抗癌协会常务理事、学术部部长、肿瘤临床化疗专业委员会主任委员、淋巴瘤专业委员会副主任委员、癌症康复会副主任委员，中国药学会药物临床评价研究专业委员会副主任委员，亚洲临床肿瘤学会副主席，国家食品药品监督管理局药品审评专家，国家科学技术奖励评审专家等职务。承担国家“十一·五”、“十二·五”重大科技专项等多项科研课题，发表文章200余篇，主编专著8部。入选百千万人才工程国家级人选，获得卫生部有突出贡献中青年专家、第二届全国中青年医学科技之星、第五届茅以升北京青年科技奖、北京市科技进步二等奖、首都劳动奖章等奖励和荣誉称号，享受国务院政府特殊津贴。



张苏展

张苏展教授，主任医师，博士导师，浙江大学医学院附属第二医院 肿瘤中心主任，浙江大学肿瘤研究所所长。现任国际大学结直肠外科协会(IUSCR)区域主席。中国抗癌协会常务理事，全国大肠癌专业委员会主任委员，中华医学会肿瘤分会常委。从事肿瘤防治工作30年，长期专研于胃肠道、乳腺、甲状腺等恶性肿瘤的综合研究和治疗。曾获1993年度美国赛克勒中国医生年度奖。曾参与国家“六五”、“七五”、“八五”、“九五”大肠癌攻关课题，主持“十一五”国家科技支撑计划项目、2项“863”课题及多项国家自然科学基金课题、省级重点课题及省部级课题。发表论文70余篇，其中SCI论文15篇。曾获国家科技进步二等奖、省科技进步一、二等奖等奖项。





周清华

周清华教授1978年毕业于华西医科大学临床医学院，1984年毕业于华西医科大学研究生院，获外科学硕士学位，并留校任助教、住院医师，从事胸外科学医疗、教学和科研工作；1988年晋升为讲师、主治医师，1992年4月破格晋升为副教授，1994年10月破格晋升为教授；1994年11月至1996年6月在美国Vanderbilt大学以高级访问教授和高级客座研究员身份从事肺癌研究工作；1996年7月回国在华西医科大学第一附属医院胸外科工作，同年12月兼任华西医科大学肿瘤研究所所长，肿瘤中心主任；1999年3月被任命为华西医科大学第三附属医院院长；1995年2月遴选为华西医科大学外科学博士生导师，1997年被国务院学位办批准为华西医科大学肿瘤学博士生导师。2006年9月由天津市政府借调到天津市，并被天津市人民政府任命为天津医科大学总医院院长和第一临床医学院院长，天津市肺癌研究所所长，天津市胸部肿瘤中心主任。

周清华教授现任天津医科大学党委常委/副校长、国际肺癌筛查和早诊专家组专家、国际肺癌学会专家组专家、国际肺癌分期专家组专家、国际肿瘤转移学会学术委员会委员、美国NIH-EDRN肺癌专家组成员，美国NIH-EDRN-CANARY肺癌专家组成员，中国卫生部肺癌专家组组长、中国肺癌早诊早治规范起草专家组组长、中国抗癌协会肺癌专委会前任主任委员、中国抗癌协会肿瘤转移专委会候任主任委员、中华人民共和国政府特殊津贴专家，跨世纪学科肿瘤学、胸外科学学科带头人。周清华教授目前担任《Thoracic Cancer》主编、《中国肺癌杂志》主编、*BMC Medicine*, *Lung Cancer*, *Molecular Cancer*, *Journal of Experimental and Clinical Cancer Research* 等二十余种国内外学术期刊主编、编委。近5年承担国家“十一五”项目2项、“863”项目4项、“973”项目2项、国际合作重大项目1项、国家自然科学基金重点项目2项、国家自然科学基金面上项目以及省部级科研项目30余项。在国内外学术期刊发表论文600多篇，主编和参编专著及教材30余部，发明专利10余项。先后获得国家科技进步三等奖、美国赛克勒中国医师年度奖，四川省和天津市科学技术一等奖，1994、2007、2011年国际肺癌学会巡回奖、2008年亚太国际肺癌巡回奖等20多项国内、国际学术奖励。



陈忠平

陈忠平 主任医师、教授、博士生导师

中山大学肿瘤防治中心神经外科主任

胶质瘤单病种首席专家

中国抗癌协会神经肿瘤专业委员会常务副主任委员

中国神经外科医师协会神经肿瘤专家委员会委员

中华医学会神经外科分会神经肿瘤专家委员会委员

广东神经外科学会副主任委员

陈忠平，江苏江阴人，1982年毕业于苏州医学院，神经外科学博士，加拿大McGill大学神经外科/肿瘤科博士后/Research Associate (1993-1999)。1999年回国在中山大学肿瘤医院筹建神经外科，任主任、教授、博士生导师。陈忠平教授从事神经外科医疗、教学和科研工作近三十年，擅长显微神经外科手术，对脑（神经系统）肿瘤的个体化综合治疗具有独到之处。在神经肿瘤分子生物学—尤其是胶质瘤耐药/放射抗拒分子机制方面做了较深入的研究，在恶性脑肿瘤免疫治疗的基础和临床应用方面（如胶质瘤融合瘤疫苗的研制、CIK细胞局部治疗胶质瘤等）也进行了探索。还在国际上首先报道了胶质瘤也存在血管生成拟态现象（Vasculogenic Mimicry）（*J Histochem Cytochem*, 2005）。发表学术论文200多篇，其中30多篇为SCI收录期刊。出版专著四部，《胶质瘤》（主编之一）、《脑肿瘤分子外科学》（副主编）、《神经系统肿瘤》（主编），和《神经系统肿瘤化疗手册》（主编）。主持编写《神经系统常见肿瘤诊疗纲要》。获包括WHO中国青年（神经科学）优秀论著奖、加拿大神经科学学会奖和2006年王忠诚中国神经外科医师年度奖（学术奖）等在内的国内、外多项学术奖励。





季加孚

季加孚教授，现任北京大学肿瘤医院，北京肿瘤医院院长，北京市肿瘤防治研究所所长，教育部恶性肿瘤发病机制及转化重点实验室主任，北京肿瘤医院肿瘤生物样本库主任，大外科主任，北京大学临床肿瘤学院胃癌诊疗协作组首席专家。

兼任中国抗癌协会副理事长，胃癌专业委员会主任委员，中国抗癌协会肿瘤医院(研究所)管理专业委员会候任主任委员。中华医学会外科学分会全国委员、国际合作部主任、胃肠专业委员会副主任委员。中国医师协会外科医师分会肿瘤外科医师委员会主任委员。NCCN胃癌临床实践指南(中国版)执笔人，卫生部胃癌诊疗规范起草专家，卫生部二级医院胃癌诊疗规范执笔专家。美国外科学院(ACS)会员，美国临床肿瘤学会(ASCO)会员，国际胃癌协会(IGCA)常委，亚洲外科学会(ASA)常委，国际外科医师暨胃肠道医师协会(IASGO)学术委员会委员，欧洲临床营养与代谢学会(ESPEN)会员，欧洲IASGO学院外科学客座教授。

研究方向主要以胃癌的临床综合治疗和分子机理，以及肿瘤遗传资源收集、标本库建立和完善为重点，作为项目负责人主持和参与消化道肿瘤临床及基础科研项目26项，承担了国家“十一五”支撑计划、“十二五”重大专项、国家“863”项目、国家自然科学基金项目、北京市科委重大项目、北京大学人类疾病基因研究中心项目等多项重大课题的研究。先后于国内外学术期刊发表论文100余篇，总影响因子149.9，编写和编译学术著作8部。培养硕士、博士、博士后研究生60余人。



邵志敏

邵志敏教授，博士生导师，首批教育部“长江学者奖励计划”特聘教授，复旦特聘教授。2000年荣获国家杰出青年基金。现任复旦大学肿瘤研究所和乳腺癌研究所所长，上海市乳腺癌临床医疗中心执行主任，复旦大学附属肿瘤医院大外科主任兼乳腺外科主任，中国抗癌协会乳腺癌专业委员会主任委员，上海市抗癌协会乳腺癌专业委员会主任委员，上海医学会肿瘤专业委员会候任主委，中华医学会肿瘤分会常委，上海市乳腺疾病防治委员会副主任委员。担任国内外多个肿瘤专业杂志常务编委、编委和审稿等，享受国务院政府特殊津贴。担任第八届亚洲乳腺癌协会主席、2013年St.Gallen乳腺癌大会专家团成员。

1998年被选为上海市卫生系统百名重点学科带头人，同年荣获中科院首届“明治乳业生命科学”奖杰出奖和首届美国加州大学洛杉矶分校校长奖。1999年被教育部聘为首批“长江学者奖励计划”特聘教授，2000年荣获国家杰出青年基金，2004年获国家科技进步二等奖和卫生部有突出贡献中青年专家称号，2005年获得上海市“十大”科技精英和上海市卫生系统领军人物，2006年荣膺中国工程院光华青年奖，2008年获全国五一劳动奖章

曾获得1997年卫生部科技进步一等奖(第二负责人)，1997年上海市科技进步二等奖(第二负责人)，1998年、1999年、2006年上海市科技进步三等奖(第一负责人)，2001、2002和2003年上海市科技进步二等奖(第一负责人)，2004年国家科技进步二等奖(第一负责人)，2008年中华医学奖三等奖(第一完成人)，2008年教育部科技进步一等奖(第一负责人)，2009年获得上海市科技进步二等奖(第一负责人)，2011年获得上海市科技进步一等奖(第一负责人)、教育部科技进步二等奖(第一负责人)，2012年领衔团队入选教育部创新团队，上海市乳腺肿瘤重点实验室及“上海市教委“重中之重临床医学中心B类”项目。

先后主持或参与包括国家杰出青年基金、国家自然科学基金、国家十五攻关课题，卫生部临床重点项目(2004-2006, 2007-2009, 2010-2012)、863项目、211工程II期、985课题、973课题及其他省部级项目共30余项。主要从事乳腺癌的临床和基础研究，科研重点为乳腺癌易感基因的研究和乳腺癌转移机制研究等。带教20余名硕士、博士和博士后研究生。在国内外肿瘤专业杂志上已发表有关乳腺癌研究的论著近350篇，其中SCI收录100余篇，被世界医学文献引用逾2800次，主编专著2本。





崔书中

崔书中，教授、主任医师、医学博士、博士生导师，广州医科大学附属肿瘤医院副院长。现任广东省抗癌协会副理事长、广东省医学会肿瘤学分会副主任委员、广东省肝脏病学会副理事长、广州抗癌协会副理事长、中华医学会放射专业委员会热疗分会副主任委员、广东省抗癌协会肿瘤热疗专业委员会主任委员、中华生物医学工程杂志编委,美国Pittsburgh大学高级访问学者。

主持研发“高精度体腔热灌注治疗系统”（PHIPES系统），于2009年12月获得SFDA批准第一个同类的Ⅲ类医疗器械注册产品，主要技术参数达到国际领先水平，建立了“高精度、大容量、循环灌注”的临床应用技术标准(PHIPES技术)，在国内近百家三甲医院广泛应用，目前正在对这一技术进行临床和基础研究（PHIPES研究）。

广州市第11届、12届人大代表

广州市第12届政协委员

2010年广州亚运会火炬手

2010年广东省五一劳动奖章

2011年广州市优秀教师

2012年获广州市“121人才梯队工程”后备人才



吴沛宏

吴沛宏，中山大学附属肿瘤医院医学影像与微创介入中心主任，主任医师，教授，博士生导师，教研室主任。美国罗彻斯特大学医学院客座教授；加拿大多伦多大学医学院客座教授。亚太肿瘤微创治疗学会常务理事、亚太肿瘤消融学会常务理事中国抗癌协会常务理事，中国抗癌协会肿瘤微创治疗专业委员会主任委员、广州抗癌协会肿瘤微创治疗专业委员会主任委员、广东省医学会细胞治疗学分会副主任委员、广东省医师协会介入医师分会副主任委员、广东省抗癌协会肿瘤影像与介入诊治专业委员会名誉主任委员、广东省放射学会常委。同时兼任《中华医学杂志》编委、《中华肿瘤学杂志》编委、《癌症》杂志常务编委。

在国内外重要期刊发表论文160余篇，其中以第一作者或通讯作者发表的SCI文章20余篇。主编专著6部。负责国家自然科学基金、国家863课题（为课题第二主持人及分题负责人）、九五攻关、卫生部、省自然科学基金、省科委、省卫生厅、211工程等项目10余项。





刘继红

刘继红，教授、主任医师、博士生导师。现任中山大学肿瘤防治中心妇科主任、宫颈癌诊治单病种管理首席专家。在澳大利亚悉尼大学获博士学位。主要研究方向为宫颈癌和卵巢癌的分子分期及淋巴结转移相关问题。擅长晚期及复发性妇科恶性肿瘤的综合治疗。

主要学术兼职：中华医学会妇科肿瘤学分会常委，广东省医学会妇产科学分会副主任委员、妇科肿瘤学组组长，中国抗癌协会妇科肿瘤专业委员会常委，广东省抗癌协会妇科肿瘤专业委员会主任委员，《癌症》杂志常务编委，《中国实用妇科与产科杂志》等杂志编委。



Boris Pasche

Boris C. Pasche, M.D., Ph.D.

Professor of Medicine

Martha Ann and David L. May Endowed Chair in Cancer Research

Director, Division of Hematology/Oncology

The University of Alabama at Birmingham

Boris Pasche is Professor of Medicine and Director of the Division of Hematology/Oncology at The University of Alabama at Birmingham (UAB). He received M.D. degrees from the Karolinska Institutet in Stockholm, Sweden and the University of Lausanne, Switzerland. He obtained a Ph.D. in coagulation research from the Karolinska Institutet and did postdoctoral research on platelet glycoproteins in the laboratory of Dr. Joseph Loscalzo, Brigham and Women Hospital, Harvard Medical School, Boston, MA. He received his training in Internal Medicine at the New York Hospital-Cornell Medical Center followed by a fellowship in Hematology/Oncology at Memorial Sloan-Kettering Cancer Center. At Sloan-Kettering he worked in the laboratory of Dr. Joan Massagué where he identified the first mutation of the type I TGF- $\beta$  receptor.

He established the Northwestern University Cancer Genetics Program and served as leader of the Cancer Genes and Molecular Targeting Program of the Robert H. Lurie Comprehensive Cancer Center. Since 2008 Professor Pasche has been Director of the Division of Hematology/Oncology of the University of Alabama at Birmingham (UAB) and holder of the Martha Ann and David L. May Chair in Cancer Research. He also served as Associate Director for Translational Research, then Deputy Director of the UAB Comprehensive Cancer Center. Clinically, he specializes in gastrointestinal tumors. Since arriving in Alabama 5 years ago he has successfully recruited 23 new faculty members, including new Directors for Bone Marrow and Stem Cell Transplantation, Hematologic Malignancies, and Genitourinary Malignancies as well as R01- and P01-funded investigators. Dr. Pasche has been the Associate Editor for Hematology/Oncology and Cancer Genetics for the Journal of the American Medical Association for the past ten years and has served on several study sections of the NIH and NCI, the American Cancer Society, the American Association for Cancer Research, and the Komen Foundation and has chaired the Department of Defense colorectal cancer review panel. Dr. Pasche was the first to hypothesize and provide the proof of concept in mice and humans<sup>1</sup> that constitutively decreased TGFBR1-mediated TGF- $\beta$  signaling predisposes to the development of several forms of cancer. He was also the first to identify an association between variants of the Adiponectin pathway and risk for breast and colorectal cancer<sup>2</sup>.

Dr. Pasche has pioneered the clinical use of amplitude-modulated electromagnetic fields. This work led to the discovery that patients with a diagnosis of cancer have biofeedback responses to tumor specific modulation frequencies. Importantly, patients with advanced hepatocellular carcinoma and breast cancer experienced long lasting clinical responses when receiving daily intrabuccal administration of very low levels of electromagnetic fields amplitude-modulated at tumor specific frequencies<sup>3</sup>. These promising clinical findings prompted initiation of reverse translational laboratory experiments aimed at identifying the mechanism of action of this novel treatment method. This research work led to the exciting discovery that cancer cell proliferation is inhibited by specific modulation frequencies<sup>4</sup>. This paradigm-changing therapeutic approach has the potential to revolutionize the treatment of cancer as it only targets tumor cells and treatment generates levels of electromagnetic fields, which are 100-1,000 times lower than those generated by hand-held cellular phones.





Sabine Tejpar

Professor Sabine Tejpar

After training in Internal medicine and Gastroenterology and a Ph.D. in the program of Molecular Oncology at the Center for Human Genetics, KULeuven, Prof. Tejpar became in Sept. 2003 an Associate Professor in the Dept of Gastroenterology, Digestive Oncology Unit, UZ Leuven. She works as a part-time clinician & part-time researcher (Senior Clinical Investigator of the Fund for Scientific Research- Flanders (Belgium)), with a focus on basic and translational research in colorectal cancer.

Her main research projects involve molecular sub classification of colorectal cancer, prognostic markers in adjuvant colorectal cancer and predictive markers for efficacy of EGFR inhibition.

Prof. Tejpar is a Member of the EORTC, Vice-chair of the EORTC TRAC (translational research advisory committee), Board member of the Gastrointestinal Group. Member of the EORTC NOCI Steering Committee and member of the Executive Committee of NOCI. She is a member of the EORTC PAMM and Laboratory Research Division, co-Chair of the EORTC-NCI-ASCO tutorial and member of the ASCO and AACR-NCI-EORTC program committee.

She has been a member of the ESMO Translational Research Working Group since 2009, a member of the BGDO (Belgian Group for Digestive Oncology) and member of the Ministerial advisory committee for colon cancer prevention in Flanders since 2006.

Finally, she is a board member of the FAPA (Belgian Familial Adenomatous Polyposis Association).





Olli Yli-Harja

Tampere University of Technology Department of Signal Processing  
Professor

During the years 1988-1992 Olli Yli-Harja was a research scientist at the Technical Research Centre of Finland, in 1993-1996 he was a lecturer in computer science in Helsinki University of Technology, and in 1997-1998 an Assistant Professor in University of Helsinki. In 1998 he was a research fellow at East Anglia University, Norwich, UK. In 1998-2001 he was a Senior researcher at the Institute of Signal Processing in Tampere University of Technology. In 2005, he was a visiting scientist in the University of Texas M. D. Anderson Cancer Center, Houston. Currently he is a Professor in the Department of Signal Processing in Tampere University of Technology, Finland and leads the Computational Systems Biology research group.

**Areas of Research:**

Dr. Yli-Harja's research interests focus on three areas in computational systems biology:

**Development of computational tools and software for systems biology utilizing advanced methods of signal processing and statistics**

This includes development and validation of software tools for systems biology with focus on image and data analysis, quantitative simulation of modern biological measurement techniques. We also develop methods for statistical inference, large scale data integration, visualization, and data mining to help interpretation of biological data. This work facilitates the use of large scale data in applied and basic research in biosciences.

**Development of computational tools and software for systems biology utilizing advanced methods of signal processing and statistics**

Cross-disciplinary applied research together with several partners in biosciences

We have a range of applications in cancer research, stem cell research, microbe-based biotechnology, yeast metabolics, transcriptional regulation, and signaling networks as well as electro-physiological modeling within mammalian cells. We aim at clinical applications related to, for example, understanding the cellular level signaling in Alzheimer's disease, and utilization clinical information using natural language processing. We also develop experimental facilities for electro-physiological measurements of mammalian neural networks, and cell image processing in an integrated microfluidic platform.

**Cross-disciplinary applied research together with several partners in biosciences:**

Basic research in theoretical biology

This includes mathematical modeling of emergent properties of complex biological systems and investigation of information processing and structure-dynamics-relationship within them. We also develop quantitative simulation methods of biological processes using advanced mathematical models.





蒋国梁

蒋国梁，复旦大学附属肿瘤医院教授、博导。现任中国抗癌协会副理事长、上海市抗癌协会理事长。复旦大学附属肿瘤医院质子重离子中心主任（筹）。2006年被美国放射学院遴选Fellow of American College of Radiology。担任日本Int J Clin Oncol等国际学术杂志的编委。主要从事肿瘤放射治疗的临床研究，重点在胸部肿瘤和胰腺、肝胆肿瘤。他也从事临床放射生物学的研究，注重于靶向药物和放疗的联合使用，正常组织和器官的放射损伤研究。近10年来，致力于国际最先进的质子和重离子肿瘤放疗研究，是“上海市质子和重离子”项目的主要建设者之一。已经在国内外学术杂志共发表论文242篇，其中SCI收录的有72篇，主编书籍6部。



Shi-Yuan Cheng

Shi-Yuan Cheng, Ph.D.  
Professor of Neurology  
Northwestern University Feinberg School of Medicine  
Chicago, USA

Professor Shi-Yuan Cheng is Professor of The Ken & Ruth Devere Department of Neurology, a member of the Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Center of Molecular Medicine at Northwestern University Feinberg School of Medicine in Chicago, IL, USA. He is also the member of AACR, ASMBM and SNO. He received his BS degree from Wuhan University in China and his Ph.D. degree from the Ohio State University in Ohio, USA. He has completed his postdoctoral training in signalling transduction and tumor angiogenesis at University of California San Diego and Ludwig Institute for Cancer Research in La Jolla, CA, USA. Professor Cheng's research interest is in the molecular mechanisms of human cancer tumorigenesis, progression, invasion/metastasis and angiogenesis. He is also interested in developing novel approaches for cancer therapies using novel anti-tumor, anti-cancer stem cells and anti-angiogenic inhibitors in combination with non-invasive evaluation methods. He contributes extensively to the US Chinese Anti-Cancer Association (USCACA) where he currently serves as the president of the USCACA.

Professor Cheng has published more than 56 research papers in top-tier, high-impact biomedical journals and a number of invited review articles and book chapters. He is currently an associate editor of *Chinese Journal of Cancer* and an editorial board member of the *Journal of Biological Chemistry*, *Neuro-Oncology*, *Journal of Neuro-Oncology* and *American Journal of Translational Research*. He is a regular reviewer for 49 peer-review scientific journals including *Nat Reviews for Cancer*, *Cancer Cell*, *PNAS*, *J Clin Investig*, *EMBO*, *Cancer Res* and many others. He has also been invited to present his research at major scientific conferences and research universities or institutions in US, Canada, Japan, China and other countries. At present, he is regular reviewer/member for study sections of National Institutes of Health (NIH), DOD, American Society of Cancer (ACS), Susan G Komen Foundation, other non-profit research foundations and funding agencies in China, Singapore, UK, Israel, Ireland and Italy.





黎孟枫

Dr. Mengfeng Li is a Cheong-Kung Professor of Microbiology, Basic Oncology and Medicine at Sun Yat-Sen University (SYSU) Zhongshan School of Medicine. He was recruited by SYSU to his current faculty position in 2006 after serving and teaching at University of Pittsburgh School of Medicine, USA. Dr. Li's research interest involves the interactions among cancer biology/microenvironment, inflammation and infection, with a focus on molecular mechanisms modulating the NF- $\kappa$ B signaling pathways in various scenario including cancer development/progression and uncontrolled inflammation. He is an author of over 50 internationally circulating and indexed research articles and supported by numerous federal/national major research grants.



马 骏

马骏，男，生于1963年8月，现任中山大学肿瘤防治中心常务副院长，教授/主任医师，博士生导师。主要研究方向为鼻咽癌个体化治疗及综合治疗。以通讯作者在肿瘤学及放射治疗学国际权威性学术期刊上发表SCI论文32篇，总影响因子200.3分，单篇最高他引163次，其中得到国内外学者高度评价和广泛引用的2篇代表性成果发表在肿瘤学国际最顶级刊物*Lancet Oncology*上。研究成果获得国家科技进步二等奖、中华医学科技一等奖及广东省科技进步一等奖各1项。





潘志忠

潘志忠，教授、博士生导师，中山大学肿瘤防治中心结肠科主任。主要从事胃肠肿瘤的诊治，擅长大肠癌的手术、化疗、放疗和生物靶向治疗，在腹腔镜手术、经肛门微创外科（TEM）、肝转移综合治疗、胃肠间质瘤靶向治疗等方面有丰富经验。现任中国抗癌协会大肠癌专业委员会副主任委员、中国抗癌协会大肠癌专业委员会肝转移学组组长、中国抗癌协会乳腺癌专业委员会委员、中华医学会肿瘤学分会青年委员、中华医学科技奖评审委员会委员、广东省医学会胃肠外科学分会副主任委员、广东省医学会外科学分会常务委员、广东省抗癌协会大肠癌专业委员会主任委员、广东省医学会结直肠肛门外科学分会委员、广东省医学会微创学分会普外科学组成员、广东省医学会医疗事故技术鉴定专家库成员、广东省中西医结合学会普通外科专业委员会委员；分别为《癌症》杂志责任编辑，《肿瘤学杂志》、《肿瘤防治杂志》、《岭南现代临床外科杂志》、《消化肿瘤杂志（电子版）》、《医学新知杂志》编委、《中国癌症防治杂志》荣誉编委。承担国家“九·五”攻关项目分课题、省、厅级科研课题6项，参与多项国家、省级课题及国际多中心肿瘤治疗研究。发表专业论著140多篇（其中SCI收录论文16篇，第一作者或通讯作者论文40篇，第一作者或通讯作者SCI论文6篇）。获2010年度广东省科技进步奖及中国抗癌协会科技进步奖2等奖、1997年度广东省科技进步奖3等奖；多次获全国肿瘤学术大会优秀论文奖；主编《大肠癌》、《造口康复与治疗：理论与实践》、《社区肿瘤防治丛书——癌症筛查与早期发现》、《社区肿瘤学》（副主编）、《中华人民共和国卫生部中国抗癌协会科普宣传系列》（副总编），参加编著普通高等教育“十一五”国家级规划教材《临床肿瘤学》、《结直肠癌》、《癌症化疗——原则与实践》、《大肠癌的基础与临床》、《中山大学附属肿瘤医院肿瘤学专题讲座》等多部专著。



李晔雄

李晔雄教授，博士，博士生导师，现任中国医学科学院肿瘤医院放疗科主任，中华医学会放射肿瘤学分会主任委员和中华放射肿瘤学杂志主编等。曾在瑞士和美国工作和学习。

主要从事恶性淋巴瘤、乳腺癌、前列腺癌和直肠癌等的治疗。承担国家和省部级重大课题。发表论文180余篇，SCI论文60余篇（*JCO*, *Blood*, *CCR*等），总影响因子200余分，单篇最高18.97分。获《新世纪百千万人才工程》国家级人选和卫生部突出贡献中青年专家，享受政府特殊津贴。



陈敏山

陈敏山教授，医学博士、博士生导师、广东省医学重点学科——肝胆肿瘤科负责人。于社会学术届中，在三十多个委员会中担任要职。曾于2009年获得中国抗癌协会科技奖二等奖和中华医学奖三等奖，并于2011年获得第五届“柯麟医学奖”。

陈敏山教授从事原发性肝癌的临床和研究工作20多年。临床上以外科为主，熟悉和掌握肝癌其它多种治疗手段，积极推广肝癌的多学科综合治疗。分别有着数千例以上肝癌切除术、血管介入治疗（TACE）和射频治疗的临床经验，并掌握肝癌的肝脏移植、放疗、化疗、生物免疫治疗、靶向药物治疗等多种方法。



赫捷

赫捷，教授、博士研究生导师。现任中国医学科学院肿瘤医院肿瘤研究所副院（所）长，肺癌中心主任，手术委员会副主任，胸外科主任。兼任中华食管疾病学组组长、中国抗癌协会食管癌专业委员会主任委员、中国抗癌协会肺癌专业委员会常委、北京胸外科协会副主任委员、《中华医学杂志》、《癌症》、《中华外科杂志》、《中华胃肠杂志》等多种杂志编委等职。赫捷教授擅长肺、食管及纵膈等胸部肿瘤的外科治疗及综合治疗，曾作为客座学者在美国俄亥俄大学及印第安那大学工作2年，有着丰富的临床实践及研究经验。以第一负责人身份完成国家“十一五”、“863”计划、北京市重大课题、国家自然科学基金及国家重点学科建设基金等研究项目。发表论著近百篇，其中SCI论文十余篇。2008获卫生部有突出贡献中青年专家。





姜文奇

姜文奇，教授，博士生导师；1982年毕业于上海医科大学。现任中山大学附属肿瘤医院内科主任，兼任深圳大学医学院院长；并担任中国医师协会肿瘤分会副会长，中国抗癌协会常务理事兼副秘书长、淋巴瘤专业委员会主任委员、化疗专业委员会候任主委等。主要研究方向为淋巴瘤的化疗和生物治疗分子机理及临床应用。主编《肿瘤生物治疗学》等。先后主持多项国家重大科技专项课题和国家自然科学基金课题。



马 军

马军教授，1955年出生，1979年赴日本东京大学医学部留学。一直致力于血液系统的良恶性疾病的诊疗，特别以治疗淋巴瘤和白血病享誉业内。

现任哈尔滨血液病肿瘤研究所所长，中国抗癌协会临床肿瘤学协作专业委员会(CSCO)基金委员会主任委员，中华医学会血液学分会副主任委员，中国医师协会血液科医师分会副会长，中国医师协会肿瘤分会副会长。1984年在国内首先建立体外多能造血祖细胞培养体系，填补国内空白。自1986年至今应用维甲酸和三氧化二砷序贯疗法治疗急性早幼粒细胞白血病1200余例，5年无病生存率72%，达到了国际先进水平。从1982年起至今，曾先后在国内外刊物上发表论文200余篇，专著40余部，获国家、省、市科技奖二十项。承担国家863重大科研项目4项，省、市级科研课题13项，开展了7项临床试验。



周芳坚

周芳坚，中山大学肿瘤防治中心泌尿外科主任、教授、博士生导师。1984-1998年，历任湖南医科大学湘雅医院泌尿外科住院医师、总住院医师、主治医师，1994年晋升为泌尿外科副教授。曾先后多次到日本北海道大学医学部及美国Miami大学、南加州大学Norris癌症中心和哈佛大学麻省总院进修或短期培训。1999年应聘到中山大学肿瘤医院创建泌尿外科，并担任科主任至今。



黄晓军

黄晓军 教授、博士生导师、主任医师  
北京大学血液病研究所所长  
北京大学人民医院血液科主任  
造血干细胞移植治疗血液病北京市重点实验室主任  
北大清华生命中心临床PI

荣誉：长江学者特聘教授  
国家杰出青年科学基金项目负责人

获奖经历：

- 2013年获欧洲骨髓移植学会颁发的“欧洲骨髓移植圣安东尼成就奖”；
- 2013年获第四届国际恶性血液病大会授予的“全球血液肿瘤学术研究杰出贡献奖”；
- 2012年入选北京市“科技北京百名领军人才培养工程”；
- 2012年获中国抗癌协会科技奖二等奖
- 2012年获教育部长江特聘教授
- 2005年入选教育部“新世纪优秀人才支持计划”
- 2011年获教育部“高等学校科学研究优秀成果奖”一等奖
- 2011年中华医学科技奖“二等奖”
- 2009年获国家技术发明二等奖
- 2008年度获中华医学科技一等奖

主要社会兼职：

- Asia Pacific Hematology Consortium (亚太血液联盟) 主席
- Asian Cellular Therapy Organization (亚洲细胞治疗组织) 候任主席
- 第九届中华医学会血液学分会主任委员
- 中国医师协会血液科医师分会会长
- 卫生部海峡两岸医药卫生交流协会血液专家委员会主任委员
- 《中华医学杂志英文版》、《中华血液学杂志》、《中国实用内科杂志》、《中国实验血液学杂志》副主编





Helen X. Chen

Helen X. Chen, M.D.  
Associate Chief and Medical Officer  
Investigational Drug Branch  
Cancer Therapy Evaluation Program (CTEP)  
National Cancer Institute (NCI)  
Helen.chen@nih.gov

Dr. Chen is a licensed medical oncologist, and joined the National Cancer Institute (NCI) in the USA in 2000. She is currently the Associated Chief and Senior Investigator at the Cancer Therapy Evaluation Program (CTEP). She is responsible for strategic planning and oversight of NCI's clinical development programs for antibody-based therapeutics and signal transduction agents including HER2/EGFR, IGF-1R and RAF/MEK targeted agents, and anti-angiogenesis therapies. She is also involved in NCI's initiatives in biomarkers and novel combination strategies, and serves on the NCI Experimental Therapeutics Committee, Angiogenesis Task Force, and the Clinical Assay Development Program. Dr. Chen is also on the organizing committee of the International Symposium of Anti-angiogenesis Therapy, the scientific committees for the EORTC-AACR-NCI Annual Meeting on Molecular Targeted Therapy, the ASCO-NCI-EORTC Annual Biomarkers Symposium, and Biotherapy Development Association (BDA). She has been an invited speaker at national and international meetings on cancer drug development strategies, and is the first or coauthor of more than 30 original and review papers in peer-reviewed journals including Journal of Clinical Oncology, Nature Reviews, and New England Journal of Medicine.



Li Yan

Li Yan, M.D., Ph.D.

Executive Director, Merck; Adjunct Professor, Peking University  
(610)213-7025; li\_yan@merck.com; yanlikyf@yahoo.com

Dr. Yan is the Executive Director and Head of Clinical Development of Oncology, Infectious Disease, and Respiratory & Immunology, and Vaccines for Emerging Markets at Merck (MSD). Dr. Yan and his team are responsible for establishing the portfolio of clinical assets spanning role, Dr. Yan was Global Director of Clinical Oncology and was responsible for developing multiple cancer drugs. His innovative approaches and critical contributions to early drug development have earned him several awards at Merck. Dr. Yan is a certified Six Sigma Green Belt and an expert in R&D process optimization. He and his team set multiple new records for clinical trial timelines received the Merck Key R&D Early Development Award. He has also played a critical role in establishing and leading the ground-breaking collaboration with Astra Zeneca to combine two investigational drugs (AKTi and MEKi inhibitors). Dr. Yan is also responsible for establishing collaborations with CTEP/NCI for the clinical development of AKT inhibitor in more than 20 cancer indications.

Prior to joining Merck, Dr. Yan spent five years at Centocor, Inc., a Johnson & Johnson company, leading both discovery and clinical development of oncology monoclonal antibodies. He led multiple discovery programs, and was the Clinical Lead of the Compound Development Team. For his contributions to the development of an anti-cancer monoclonal antibody, he received the Philip Hoffmann's Scientific Award, the 2nd most prestigious award at Johnson & Johnson.

Dr. Yan received his M.D. from the Medical College of Peking University and his post-graduate training at Beijing Cancer Hospital, Peking University, where he now serves as an adjunct professor. He studied tumor biology and received his PhD at University of Kansas Medical Center. He then completed a fellowship at Children's Hospital Boston focused on tumor angiogenesis in the Department of Surgery chaired by Dr. Judah Folkman, the pioneer of tumor angiogenesis. Dr. Yan was an instructor (assistant professor) at Harvard Medical School. He has published more than 70 peer-reviewed manuscripts and 5 book chapters, and is a frequent speaker and organizer of international conferences of tumor biology, antibody therapeutics, cancer drug R&D, and global clinical collaborations. Dr. Yan is a recipient of American Association for Cancer Research AFLAC Scholar in Cancer Research Award, and China SFDA Special Contribution Award. He is senior associate editor of Chinese Journal of Cancer, and serves as editorial board member and reviewer for various cancer journals.

Dr. Yan serves as a founding member of US Chinese Anti-Cancer Association (USCACA), advisory panel member of Chinese Society for Clinical Oncology (CSCO), the Vice President of Sino American Pharmaceutical Association (SAPA), and was President of the SAPA Greater Philadelphia (2008-2009). He is also a member of BayHelix, an organization of leaders of Chinese heritage in the global life sciences and healthcare community.





Xiao Xu

Xiao Xu, Ph.D., President of ACEA Biosciences, and Director of Hangzhou High Throughput Drug Screening Center.

Dr Xiao Xu is the President of ACEA Biosciences Inc. ACEA Biosciences is a San Diego based biotechnology company. He also is the Director of Hangzhou High Throughput Drug Screening Center. Prior to joining ACEA, Dr. Xu was Director of Gene Expression and Amplification at Nanogen, Inc., leading a team to develop applications of genetic diagnostics. Prior to Nanogen, Dr. Xu was Staff Research Investigator in Gladstone Institutes, University of California San Francisco, where he was a principal investigator on Alzheimer Disease research grants from NIH and California State Government. Dr. Xu received postdoctoral training in US Centers for Disease Control, and The Scripps Research Institute at La Jolla, California in molecular virology and cancer biology, after he completed his Ph.D. program in Zhejiang University in China. Dr. Xu owns over 15 US patents and filed more than 15 patent applications, and has published over 60 research articles in International Journals including Science, PNAS, Nature Biotechnology, and Chemistry & Biology.



Wenru Song

Wenru Song, MD, PhD

Dr. Song is the Head of Regional Oncology Development in Asia-Pacific at Millennium: The Takeda Oncology Company. Prior to join Millennium, Dr. Song was a medical director/clinical lead at Pfizer Oncology where he led a number of biologic compounds in cancer immunotherapeutics and antibody-drug conjugate programs. Before joining the pharma-industry, he was an associate investigator at Baylor Institute of Immunology Research and an attending oncologist physician at Baylor Sammons Cancer Center in Dallas. He studied Medicine at Shandong University in China before coming to the US for his PhD study in Immunology. He then did his postdoctoral fellowship in cancer immunotherapy with Dr. Ron Crystal at Cornell University Medical Center, his medical residency at Montefiore Medical Center/Albert Einstein College of Medicine, and at Stanford University for his clinical oncology fellowship and research in cancer immunotherapy with Drs. Ron Levy and Ed Engleman. Dr. Song is board-certified in medical oncology and internal medicine by the American Board of Internal Medicine.

Dr. Song's clinical interest is on medical oncology, especially lymphoma, and his own lab research had been focused on the development of effective cancer immunotherapy. With the approval of three Investigational New Drug applications from the US FDA, he started to translate his lab research in cancer immunotherapy by initiating phase I/II human clinical trials in patients with colon or pancreatic cancer at Stanford University and in patients with lymphoma at Baylor Sammons Cancer Center. Dr. Song has broad experience in translational and clinical research in oncology drug development in a variety of hematological and solid tumor types in both academic and industry settings.

Dr. Song has actively participated in community services and professional organizations, a founding board member and ex-board chair as well as the ex-president of the Chinese American Hematologist and Oncologist Network (CAHON), a member of Ad Hoc Committee in International Outreach at American Society of Hematology, an overseas member in the Executive Committee of Chinese Society of Clinical Oncology, a member of the Development Committee and the Industry Council at the Society for Immunotherapy of Cancer (SITC), a member of Career Development Committee at American Society of Clinical Oncology, a member of the NCI's Immune Response Modifier Pathway Prioritization Working Group, a member of the SITC-FDA-NCI Taskforce on Cancer Immunotherapy Biomarkers, and most recently as a member of World Immunotherapy Council.





陈可欣

陈可欣，女，在中国天津医科大学获得肿瘤学博士学位，于2006-2007年在美国MD Anderson 肿瘤中心完成博士后研究工作。1987年任职天津医科大学附属肿瘤医院至今，现任天津医科大学附属肿瘤医院研究所流行病学研究室和组织生物标本库主任，博士生导师，教育部创新团队学术带头人，“211工程”公共卫生与预防医学流行病学与卫生统计学学科带头人，世界卫生组织（WHO）国际肿瘤登记报告协会（IACR）会员，美国国家肿瘤登记协会会员（NCRA），中国抗癌协会肿瘤流行病学专业委员会常委，美国癌症研究协会（AACR）会员。主要研究领域为肿瘤流行病学研究工作，集中于描述天津恶性肿瘤的流行趋势、开展常见恶性肿瘤的早期筛查和肿瘤分子流行病学的研究方面。先后主持和参加30余项各级科研课题，包括主持“重大新药创制”科技重大专项“十二五”实施计划1项、国家重大卫生公共项目、卫生部中央财政转移支付项目、国家自然科学基金项和天津市科委重大项目2项，经费超过2380万。获得过5项省部级以上科技进步奖，作为副主编或参与编写专著12部。发表学术论文80余篇，SCI论文38篇，发表于 *Cancer Research*, *Clinical Cancer Research*, *Carcinogenesis* 和 *CEBP* 等杂志上。



Sven Tang

Sven Tang, M.D.  
Medical Director of Inventiv Health Care  
Science Park, Singapore

Dr. Tang received his medical degree at China Medical University in Shenyang, China. Then he joined the Oncology department of First Hospital of China Medical University as a surgical Oncologist. He was certificated as a Surgical Oncologist.


During his career in pharmaceutical industry as Medical Advisor and Therapeutic Area Head responsible for Asia Pacific region, Dr. Tang has been involved in the development of both pre market and in market study drugs for a variety of indications as colorectal cancer, gastric carcinoma, head and neck cancer, NSCLC, Lymphoma and Multiple Myeloma. Dr. Tang was involved in scientific project and published as the first author or co-first author in the peer reviewed journals.


Dr. Tang joined Inventiv in 2013 and is based in our Singapore office as Medical Director Asia Pacific. Within this role Dr. Tang took over responsibility and medical oversight for phase I-IV clinical studies in various Oncology and Hematology indications.



# 广州白云国际会议中心功能分布图

## Functions Distribution





## 会场分布/Meeting Location

大会 ( 11月8日、9日 08:30-12:00 ) : 2号楼4楼广东大会堂

General Session : Guangdong Grand Conference Hall (Floor 4, Building 2)

基础、转化分会场: 4号楼1楼越秀华堂

Basic & Translational Medicine Session: Yuexiu Grand Hall (Floor 1, Building 4)

临床分会场: 1号楼1楼清和厅

Clinical Session: Qinghe Room (Floor 1, Building 1)



# Chinese Journal of Cancer (《癌症》杂志)

Chinese Journal of Cancer (CJC) 的前身是创办于1982年的《癌症》杂志，于2010年变更文种为英文出版。创刊三十余年来，得到主办单位中山大学肿瘤防治中心的全力支持，在国内肿瘤学期刊中一直处于领军地位：

2010、2011、2012、2013年连续四年荣获“中国百种杰出学术期刊”称号，2012年荣获“中国国际影响力优秀期刊”称号。2008、2011年分别入选第一届和第二届中国精品科技期刊名单。



为了进一步提升了杂志的显示度，采取了以下措施：（1）引入国际化审稿系统ScholarOne；（2）在选稿机制上，按国际惯例，实行了“责任编委制”；（3）建立了包括美国、英国、法国、瑞士、瑞典、新加坡、芬兰、加拿大、意大利等十多个国家和地区专家组成的国际性编委会，保障了稿源和审稿的国际化；（4）成为中国抗癌协会和美中抗癌协会这两个重要学术协会会刊；（5）积极参与国际学术交流，主办和协办了多次国际性和国内高水平学术会议，成功实现会议约稿。

CJC一直在朝既定的目标前进，并且发展态势良好，国际影响力不断提高：

2002年 Chinese Journal of Cancer (《癌症》) 被收录入世界权威生物医学检索系统 PubMed/Medline，2012年被PubMed Center和目前最权威、认知度最高的开放存取期刊目录 DOAJ收录。





# 广州白云国际会议中心地图

